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Abstract 
Alzheimer’s disease (AD) is the most common form of dementia affecting millions of 
people worldwide. Pathologically, AD is characterised by neurofibrillary tangles, amyloid plaques 
and synaptic atrophy. Synaptic dysfunction occurs early in AD and is recognized as a primary 
pathologic target for AD treatment. Synapse degeneration or dysfunction contributes to clinical 
signs of dementia through altered neuronal communication, and the degree of synaptic loss strongly 
correlates with cognitive impairment. However, the molecular mechanism underlying synaptic 
pathology remains largely unknown.  
The aim of this dissertation was to get a better understanding of the synaptic proteome in 
AD brain.  
The first aim was to use two-dimensional differential in-gel electrophoresis (2D-DIGE) to 
assess the levels of synaptosomal proteins in AD by comparing severely affected and relatively 
spared areas of the brain in each disease state. Six female AD and six female non-AD cases were 
used. Within each diseased state, two vulnerable areas (hippocampus and temporal cortex) were 
compared with two relatively spared areas (motor and occipital cortices). Then, proteins exhibiting 
significant expression differences were identified using matrix-assisted laser desorption/ionisation 
time-of-flight mass spectrometry, electrospray ionisation quadrupole time-of-flight mass 
spectrometry, and online database searching. A total of 871 protein spots were detected. Of these, 26 
unique synaptic proteins showed more than two-fold differences in level of expression between AD 
and non-AD subjects. These proteins are involved in signal transduction, structure, energy 
metabolism, vesicle transport, and antioxidant activity. 
Multiple reaction monitoring (MRM) has emerged as a useful mass spectrometry technique 
for quantitative protein analysis to verify and validate biomarkers. The second aim of this project 
was to develop a methodology for targeted label-free quantitative analysis of synaptosomal proteins 
from human autopsy tissue using MRM with high performance liquid chromatography coupled with 
triple quadrupole-linear ion trap mass spectrometry. The protein enolase from Streptococcus 
pyogenes serotype M6 was used as an internal standard. Using this method, relatively low abundant 
proteins were quantified in a highly reproducible manner.  
The developed MRM assay was applied to validate the results from 2D-DIGE analysis. 
Severely affected hippocampus was compared with motor cortex, a relatively spared region. Major 
outcomes of this study were that significantly higher expression levels of peroxiredoxin-1 (may 
provide antioxidant protection) and dihydropyrimidinase-related protein-1 (associated with 
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cytoskeletal remodelling) were found in AD hippocampus when compared with AD motor cortex. 
Furthermore, peroxiredoxin-1, fructose-bisphosphate aldolase and creatine kinase B (energy-related 
enzymes) were significantly down-regulated in non-AD hippocampus when compared with non-AD 
motor cortex. Both differences and similarities were detected between 2D-DIGE and MRM analysis. 
Current estimate of total protein numbers in a human synapse is around 3000 proteins. 
However, two-dimensional electrophoresis separation of synaptosomal fraction revealed a mere 871 
protein spots (includes proteins with post-translational modifications, alternatively spliced forms 
and isoforms). The aim of the last part of this project was to quantitatively study the synaptic 
proteome by using strong cation exchange separation prior to SWATH (sequential window 
acquisition of all theoretical fragment-ion spectra) analysis. SWATH is a relatively new technique 
that provides MRM-like reproducibility but with higher multiplexing. A total of 2077 different 
proteins were identified; 36 proteins exhibited significant differences in expression between AD or 
non-AD hippocampus when compared with motor cortex, and displayed greater than 1.5-fold 
differences between AD log2FC (fold change) and non-AD log2FC. Of these, 17 are novel proteins, 
and 13 proteins have previously been implicated in AD. Ingenuity Pathway Analysis revealed that 
that differentially regulated proteins are related to cellular assembly and organization, cellular 
function and maintenance, and nervous system development and function.   
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Introduction 
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The studies described in this thesis were performed to understand the synaptic 
proteome in human Alzheimer’s disease (AD) brain. Synaptic dysfunction is a primary 
pathology for AD and contributes to clinical dementia. The current understanding of the 
literature is that the degree of synaptic loss correlates with cognitive impairment. For the past 
few decades, many studies have strived to understand the synaptic pathology in AD using 
post-mortem tissue, cerebral spinal fluid, serum and blood from human and transgenic animal 
models. Despite this, the molecular mechanisms underlying synaptic degeneration are largely 
unclear. My approach to identify abnormally expressed synaptic proteins in AD will help to 
elucidate those mechanisms.  
The term proteome refers to the entire proteins expressed by a genome, or by a tissue, 
or a cell at a particular moment in time, under defined conditions. The goal of proteomics is 
to identify and quantify those proteins and their isoforms. Comparative quantitative analysis 
of a proteome from the synapses of AD autopsy tissue with those from non-AD tissue could 
detect proteins that are differentially expressed, and those proteins may have functional 
consequences; thus, resulting in the pathophysiological conditions. We used both gel-based 
(two-dimensional differential in-gel electrophoresis with electrospray ionisation quadrupole 
time-of-flight mass spectrometry or matrix-associated laser desorption/ionisation time-of-
flight mass spectrometry) and gel-free proteomics (multiple reaction monitoring  with 
hybrid triple quadrupole mass spectrometry, and SWATH-based acquisition with electrospray 
ionisation quadrupole time-of-flight mass spectrometry) to separate, identify and 
quantitatively analyse synaptosomal fractions from AD and non-AD brain. We found 
abnormally expressed proteins that have been implicated in AD pathology or aetiology in 
other studies, as well as several novel proteins. The studies described in this thesis could 
potentially contribute to methodological development in neuroproteomics, as well as to 
expanding our current understanding of the synaptic pathogenesis of AD.  
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2.1. Alzheimer’s disease 
2.1.1. Societal burden 
Alzheimer’s disease (AD) is an age-dependent neurodegenerative disorder that 
progressively impairs cognitive and memory function. It is the most common form of 
dementia in the elderly, and affects more than 25 million individuals worldwide
1
. In Australia, 
more than 320,000 people are living with dementia, and this number is expected to reach 
400,000 by 2022, and 900,000 by 2050 without a medical breakthrough
2
. Dementia is the 
third leading cause of death
3
, and third leading cause of disability burden in Australia
2
. In 
2009 and 2010, the total annual cost for direct health and aged care system amounted to $4.9 
billion, and is projected to be $83 billion by 2060s (in 2006-2007 dollars)
4
. With the 
population aging rapidly, AD has become an enormous medical and socio-economical 
problem in developed countries. 
AD is classified into early-onset (<65 years) and late-onset (>65 years) forms
5
. Early-
onset AD is rare, with an incidence rate of 4.2 per 100,000 persons aged 45 to 64
6
. The most 
significant risk factor for late-onset dementia is age; the risk doubles every five years after 
the age of 65
7
. Pathological brain changes may stay asymptomatic up to 30 years, and the 
symptomatic phase can last for 5-12 years
8
. Median life expectancy after initial diagnosis is 
between five and ten years
9
. AD not only causes deterioration of cognitive functions, it leads 
to institutionalization and ultimately death. Currently, there is no cure for AD. Approved 
drugs can delay the progression of the disease, and help to provide quality of life for the 
patients and caregivers
10
; however, these drugs do not positively influence the progression of 
AD pathology. Furthermore, although treatment is most effective when initiated as early as 
possible, early diagnosis remains a problem. 
2.1.2. Clinical symptoms 
The initial clinical symptom of AD is memory loss, particularly of recently learned 
information, which the patient could easily dismiss as a normal sign of aging. As the disease 
progresses, cognitive functions including memory, comprehension, orientation, and judgment 
are gradually lost. AD patients experience changes in personality and behaviour such as 
depression, delusions, mood swings and aggressiveness. Eventually, patients lose control over 
bodily functions, becoming completely socially dependent.  
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2.1.3. Diagnosis 
2.1.3.1. Clinical diagnosis 
Currently, the diagnosis of probable AD is made based on clinical assessment using 
the criteria set out in the National Institute of Neurological and Communicative Diseases and 
Stroke-Alzheimer’s Disease and Related Disorders Association and the Diagnostic and 
Statistical Manual of Mental Disorders
11
. Clinically, no single test can identify AD. In 
addition to clinical consultation, medical history, a test of intellectual function, physical and 
neurological examination, neuropsychological tests, medical imaging, psychiatric assessment, 
lumbar puncture, and blood and urine tests are used for clinical diagnosis
12
. However, 
antemortem clinical diagnosis only provides 80-90% accuracy; diagnostic accuracy is lower 
in non-specialised settings, especially in mild stages
13
. 
2.1.3.2. Neuropathological diagnosis 
A definitive diagnosis of AD can be made only through histopathological examination 
of autopsy tissue after death. AD brain shows neuronal atrophy in selected regions of the 
brain, including hippocampus, and temporal and frontal cortices. Pathological criteria 
including Consortium to Establish a Registry for Alzheimer’s Disease (CERAD)14, Braak and 
Braak staging
15
, and the National Institute for Aging and Ronald and Nancy Reagan Institute 
of the Alzheimer’s Association (NIA-RIA) criteria are internationally accepted16.  
2.1.3.2.1. CERAD  
The first CERAD criterion uses Bielschowsky staining to count the number of 
neuritic and diffuse plaques in the caudate-putamen complex, amygdala, and parieto-occipital 
sulcus. The cases are classified into three stages: Stage A is less than 2 neuritic plaques per 
100 light microscopic field; stage B is approximately 6; stage C is more than 30. A patient is 
diagnosed with AD in case of stage A if s/he is younger than 50 years old, stage B if between 
50 and 75, and stage C if older than 75. In addition to light microscopic diagnosis, CERAD 
criteria incorporate the patients’ family history, neuropsychology, and neuropathology when 
diagnosing AD. 
The CERAD criteria inevitably introduce human error because of examiner variation. 
However, they are appropriate for clinical studies because they include the patients’ clinical 
information in the diagnosis
17
. 
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2.1.3.2.2. Braak and Braak staging 
As will be discussed in section 2.1.4.2., the accumulation of neurofibrillary tangles is 
a major pathological hallmark of AD. Braak’s procedure divides AD pathology into six stages 
based on the morphological distribution pattern of neurofibrillary tangles (NFT). Stage I is 
characterised by mild accumulation of NFT in the transentorhinal area, which then spread to 
the entorhinal region in stage II. In stage III, the hippocampus is affected, and the number is 
increased in stage IV. The neocortex is altered in stage V, and finally the primary cortex in 
stage VI. The six stages are divided into three phases: transentorhinal (stages I & II), limbic 
(stages III & IV) and neocortical (stages V & VI) (Figure 2.1). The first phase corresponds to 
cognitive normality, the second to cognitive impairment, and the third to dementia. 
Neuropathological diagnosis using Braak and Braak staging requires a unique 
staining protocol to examine NFT distribution, and does not include clinical information 
when diagnosing AD. However, it has proven to be highly specific and moderately sensitive, 
and suitable for research
17
. 
 
 
Figure 2.1 Braak and Braak’s staging of neurofibrillary tangle deposition in Alzheimer’s 
disease brain. A single layer of transentorhinal region is affected in stages I-II, which spreads 
to limbic regions such as the hippocampus in stages III-IV, and then to the isocortical regions 
in stages V-VI
15
. 
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2.1.3.2.3. NIA-RIA 
The NIA-RIA classifies the patient as having a high probability of developing AD if 
the Braak and Braak stage is V/VI and CERAD stage is C. Braak and Braak stage III/IV and 
CERAD stage B predicts an intermediate probability of AD. Finally, patients with Braak and 
Braak stage I/II and CERAD stage A are classified as having low probability of developing 
AD, regardless of a clinical presentation of dementia. 
The combination of Braak and Braak staging and CERAD criteria makes the NIA-
RIA highly specific. However, it has low sensitivity
17
. 
2.1.4. Pathological hallmarks 
2.1.4.1. Amyloid plaques 
The accumulation of amyloid beta peptide (A) has been the focal point of AD studies 
for over a decade, and is widely considered to be the causative component of AD 
pathogenesis
18
. The peptide is generated through proteolysis from the amyloid precursor 
protein (APP). APP is found in various sites within the neuron, including synaptic membranes, 
postsynaptic densities, dendrites, and axons. APP, an integral membrane protein, is cleaved 
by either secretase or secretase, and the resulting transmembrane domain is cleaved by 
secretase. APP proteolysis by secretase generates nontoxic products, whereas the 
secretase-induced cleavage product is further processed to generate A peptides of various 
lengths, including A42, the most pathogenic species of AD. A42 readily forms neurotoxic 
fibrillar extracellular deposits of plaques (Figure 2.2) in the brains of AD patients
19
. 
Despite the extensive ongoing studies on A and APP, the exact mechanism by which 
it causes synapse degeneration is unknown. Decreased levels of APP in an animal model 
leads to the abnormal expression of synaptic markers, and the arborisation of axons and 
dendrites, along with behavioural and neurological dysfunction
20
. Similarly, the synaptic 
marker, synaptophysin, shows lower levels in the hippocampus of transgenic mice that 
overexpress APP, prior to A deposition21. It is interesting to note that during rat brain 
development, APP expression peaks during synapse formation
22
. These results suggest that 
APP is involved in synaptic maintenance and plasticity, and that disturbed APP metabolism 
may initiate pathological changes in the synapse even before plaque formation.  
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Figure 2.2 Amyloid plaques and neurofibrillary tangles (adopted from
23
). 
 
2.1.4.2. Neurofibrillary tangles 
Tau is a phosphoprotein abundantly expressed in neurons and to the lesser extent in 
astrocytes and oligodendrocytes in brain
24
. It is the major microtubule-associated protein that 
copolymerises with tubulin to induce microtubule formation, and control the stability of the 
microtubules under normal conditions. In AD, tau is abnormally hyperphosphorylated at 
certain residues to form paired helical filaments
25
, which aggregate into NFT inside the 
neurons (Figure 2.2). As a result, microtubules lose stability, which disturbs neuronal 
structure and intracellular transport system
26, 27
. It is now widely accepted that the extent of 
tau phosphorylation correlates with the severity of dementia. Braak and Braak proposed a 
model for diagnosing the severity of AD based on the pattern of NFT deposition
15
, as 
explained in section 2.1.3.2.2. 
The level of synaptophysin mRNA is significantly lower in hippocampal neurons 
containing NFTs than in NFT-free neurons
27
. Lower expression of synapse-associated 
proteins is also a consequence of abnormal tau phosphorylation in the absence of NFTs in 
situ
28
. NFTs disturb the stability and function of cytoskeletons, affecting the neuronal 
transport system with consequences.  
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2.1.4.3. Synaptic degeneration 
Synaptic degeneration is the best neurobiological correlate of loss of cognitive 
function in AD
29
. Quantitative studies using immunohistochemistry or electron microscopy 
have shown area-specific deterioration with significantly lower neuronal and synaptic 
densities in AD brain
29, 30
; hippocampus appears to be most severely affected and occipital 
the least
31-33
. A quantitative morphometric study by Davis el al. (1987) on frontal and 
temporal cortices showed 25% to 35% decrease of synapses and 15% to 35% loss in the 
number of synapses per neuron
34
. In response to loss of synapses per volume, the size of the 
remaining post synaptic appositions increases in AD
35
. This compensatory response is seen in 
mild to moderate AD cases. In severe cases, continued synaptic loss without such a response 
is observed; this causes a greater loss of synaptic density
30
. More than 90% of the dendritic 
surfaces are in contact with synapses and are vulnerable since they are distant from the 
supportive function of the cell body. Coleman’s group (1979) showed that the degenerative 
processes start in the more distal dendrites
36
. 
Synaptic loss occurs not only from neuronal death; surviving neurons also lose synapses 
in AD
37
. In addition, synaptic function is impaired. Synapses that appear to be structurally 
intact may be dysfunctional. Altered synaptic functionality can result from defects in 
synthesis, transport, release and reuptake of neurotransmitters; altered vesicle trafficking
38
; 
reduced metabolic activity; reduced or altered transmitter receptors, pumps, transporters, and 
ion channels; and defects in second messenger systems. In AD, the regulation of synaptic 
activity is interrupted, leading to loss of synaptic maintenance, excitotoxicity and, ultimately, 
loss of stored memory
39
. Such molecular changes have also been seen in functional neurons 
and dysfunctional synapses.  
 
2.2. Synapse 
2.2.1. Structure 
The brain is the centre of the nervous system, and comprises more than 100 billion 
neurons. This complex biological structure moves signals from neuron to neuron across 
specialised junctions called synapses. A synapse is composed of a presynaptic component 
(axon terminal), a synaptic cleft, and a postsynaptic component (dendritic spine or cell soma) 
(Figure 2.3). A presynaptic ending can be identified by the presence of neurotransmitter-filled 
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vesicles, smooth endoplasmic reticulum, mitochondria, neurofilaments, and microtubules. A 
synaptic cleft is composed of a dense plaque of intercellular material that separates the pre- 
and postsynaptic membranes. The postsynaptic component includes the postsynaptic density, 
which consists of cytoskeletal structures and cisternæ  of the smooth endoplasmic reticulum, 
and contains signal transduction molecules involved in regulating the localisation and 
function of receptors
40
.  
 
 
Figure 2.3 Electron micrograph of a synapse (magnification x 56,000). The round dark 
structures are mitochondria (M) and smaller round bodies are vesicles (V) that contain 
neurotransmitter. P, postsynaptic density; S, synaptic knob; D, dendrite. (adopted from
41
) 
 
2.2.2. Function 
The synapse plays a major role in cell-to-cell communication. Information in the brain 
is stored as a consequence of synaptic plasticity, which works by altering the chemistry and 
structure of synapses; or by the elimination of old and the formation of new synapses
42
. Upon 
arrival of the action potential from the axon, the synaptic signal-transduction machinery and 
neurotransmitter receptors respond by initiating biochemical changes, which ultimately 
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modifies brain circuitry in response to behavioural experience. Hence, precise control of 
synapses is crucial for normal brain function. For normal synaptic function, gene products 
that form pre- and postsynaptic membrane complexes need to be regulated, post-
translationally processed, and transported. Protein complexes forming receptors also need to 
be made, assembled and inserted into membranes. Neurotransmitters need to be synthesised, 
and their release needs to be balanced with vesicle trafficking. And the energy required for all 
these actions must be supplied
43
. As synapse degeneration is the first pathological event to 
occur in neurodegenerative disorders, including AD, synapses have been designated as a 
primary pathologic target. Proteomic studies have compiled a first draft of the synaptic 
protein composition, and showed high degree of molecular complexity. 
2.2.3. Synaptosomes 
The term synaptosome was first introduced by Whittaker and colleagues in 1964
44
. 
They described the synaptosome as “pinched-off nerve endings” as the axon terminals are 
snapped or torn off during homogenisation and they naturally reseal to form membranous 
sacs
41
. The first synaptosome isolation was carried out by Hebb and Whittaker in 1958 using 
differential and density-gradient centrifugation
45
. Synaptosomes contain a complete suite of 
presynaptic components, postsynaptic membranes, and the postsynaptic density. Schrimpf’s 
group (2005) studied the morphology of the synaptosomal fraction isolated from mouse brain 
using electron microscopy
46
. The molecular machinery for neurotransmitter release, uptake 
and storage remain intact in synaptosomes prepared from fresh tissue
41
 as well as those 
isolated from human brain that has been frozen
47-49. In addition, Daniel’s group (2012) have 
shown that isolated synaptosomes can be frozen and stored prior to quantitative analysis, 
instead of preparing fresh synaptosomes
50
. 
 
2.3.Neuroproteomics 
2.3.1. Background 
Over the past decade, various proteomic techniques have been used to study global 
protein expression profiles of tissues
51-55
, plasma
56-59
, serum
60-62
 and cerebrospinal fluid 
(CSF)
59, 63-67
, and to compare the profiles of physiological and diseased states. Proteomics 
allows the researcher to identify molecular markers in an unbiased manner and gain greater 
understanding of the mechanisms underlying disease pathology. The ultimate goal of 
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proteomics study is to identify all the proteins present in the sample, as well as their 
biological activities, modifications and protein-protein interactions. Neuroproteomics is the 
sub-field of proteomics focused on the study of the central nervous system. Proteomics is 
perfect for studying neurodegenerative and neuropsychiatric diseases as their pathology 
involves multiple interacting proteins
68
. Post-mortem tissue provides a great platform for 
studying neurological diseases; however, the complexity of the human brain makes it 
challenging for protein analysis. Firstly, each brain region is anatomically-defined, and 
associated with specific behaviours: hippocampus is involved in spatial learning, striatum is 
involved in reward-based learning and movement control, cerebral cortex is involved in 
decision making and sensory perception, and amygdala is involved in emotional responses, 
etc. Secondly, there is cellular heterogeneity within each brain region. Thirdly, neurons have 
high levels of compartmentalisation with axons, dendrites, and cell bodies. Hence, various 
front-end sample processing strategies are often used for sample complexity reduction and 
sample enrichment, including subcellular fractionation, which is used to isolate cellular 
compartments such as synaptosomes (see section 2.2.3.), and chromatographic approaches 
such as strong cation exchange (SCX) fractionation. In SCX fractionation, peptides are 
captured by binding to negatively charged resin; strongly basic analytes are more tightly 
bound than acidic ones. The resin is washed with a salt gradient, which neutralises the ionic 
interaction and elutes similarly-charged molecules in small fractions. This maximises the 
ability to discover meaningful changes in protein abundances due to the decreased 
complexity of each fraction and the resulting enrichment of low-abundant proteins. 
Furthermore, advances in mass spectrometric platforms have led to reproducible quantitative 
neuroproteomics, which aims to evaluate relative or absolute protein abundance from 
diseased tissue. 
2.3.2. Two-dimensional gel electrophoresis 
The first step in any proteomics analysis is to separate the proteins present in a sample, 
either whole tissue or front-end fractionated, from each other. One approach to protein 
separation is through the use of two-dimensional electrophoresis (2-DE). Firstly, the proteins 
are separated according to their isoelectric points, and then by their molecular weight in the 
second dimension
69
. The isoelectric point is the pH at which the net charge on the protein is 
zero. Within an electric field, proteins with a negative charge will move along a pH gradient 
towards the anode, becoming progressively less negative until the protein has net charge of 
P a g e | 15 
zero (when proteins are moving along a pH gradient). Proteins with a positive charge will 
move along the gradient towards the cathode, until they too have a net charge of zero. The 
use of polyacrylamide gel was first described in 1959
70
, and the use of isoelectric point theory 
plus carrier ampholytes (amphoteric electrolytes) was first introduced during the 1960’s71, 72. 
The combination of two techniques, 2-DE, was established in the 1970’s73, 74. Soon after, 
immobilised pH gradient (IPG) strips were created to overcome the limitations of carrier 
ampholytes, such as poor reproducibility and resolution
75
. Now, different types of IPG strips 
are commercially available: 7 cm to 24 cm long strips with varying pH gradients including 
wide (8 pH units), medium (3-5 pH units) and narrow (1 pH unit) ranges. Separation on IPG 
strips is now a standard first-dimension step for in-gel proteomics procedures, and the wide 
ranges of pH gradients available make it a useful technique for many different protein 
samples. 
Even in a fractionated protein sample, there is likely to be more than one protein 
within any given isoelectric point. To further separate out the proteins so that each can be 
seen individually, they undergo a second dimension separation, which separates proteins by 
molecular weight - sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). 
After the first-dimension separation, disulfide bonds are reduced (i.e. broken) to allow 
optimal unfolding of the protein’s tertiary structure, and then the exposed sulfhydryl groups 
are alkylated to prevent reformation. This procedure ensures that each protein will be fully 
unfolded so that all species of a given protein will have the same unfolded, tertiary structure 
and therefore molecular weight. A typical high resolution 2-DE gel can separate up to 
thousands of protein, and the intensity of the protein spots is used to compare protein 
abundance from different samples. 
Two-dimensional differential in-gel electrophoresis (2D-DIGE) is the latest 
innovation of 2-DE, which is used to detect differences in protein abundance between 
diseased and control tissues within the same gel. This technique involves labelling of two 
protein extracts with fluorescent Cy3 and Cy5, and a pooled internal standard composed of 
all samples with Cy2; the internal standard is used to minimise gel to gel variation to give 
enhanced qualitative and quantitative analysis (Figure 2.4). The dyes differ in excitation and 
emission wavelengths but have identical isoelectric points and similar molecular weights. 
Three labelled proteins are mixed, run on the same 2-DE gel, and samples labelled with 
different CyDyes are visualised separately using a scanner. By analysing the scanned images, 
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the differences in the protein abundances between the two samples can be detected
76
. The 2-
DE and 2D-DIGE coupled with MS-based protein identification allows the investigator to 
visualise and detect abundance changes of hundreds of proteins on one gel. However, this 
gel-based approach makes it difficult to study membrane proteins and proteins with 
extremely high or low isoelectric points. Also, large numbers of sample cases cannot be 
analysed in a single experiment. 
 
 
Figure 2.4 Schematic diagram of 2D-DIGE experiment. Protein extracts are labelled with 
either fluorescent Cy3 or Cy5, and equal amount of proteins from all the samples are pooled 
(internal standard), then labelled with Cy2. Three labelled protein extracts are mixed, 
separated on a 2-DE gel, visualised separately using a scanner, and then each protein spot is 
quantitatively compared. 
 
2.3.3. Mass spectrometry  
2.3.3.1. Overview 
Separated proteins can then be identified via a powerful technique called mass 
spectrometry (MS). In MS, enzyme-digested peptides are electrically isolated forming gas-
phase ions and separated according to their mass-to-charge ratios (m/z). The resulting 
spectrum gives information about the amino acid sequence of each peptide. By comparison to 
a bioinformatics database, proteins can then be identified
77
. There are various methods of 
generating ions including matrix-assisted laser desorption/ionization (MALDI)
78
 and 
electrospray ionisation (ESI)
79
. 
P a g e | 17 
2.3.3.2. Ionisation  
2.3.3.2.1. Matrix-assisted laser desorption/ionisation  
In MALDI
80, 81
, the sample is mixed with a matrix that has a capability of absorbing 
energy from the laser at 337 nm wavelength, spotted on a MALDI plate, and air-dried. 
Commonly used matrix compounds include sinapinic acid, α-cyano-4-hydroxycinnamic acid 
and 2, 5-dihydroxybenzoic acid; matrix compounds are selected depending on the type of 
analytes being ionised. The MALDI plate is inserted into the vacuum region of the mass 
spectrometer. Irradiation with short laser pulses causes the components in the analyte-matrix 
crystals to transform into gas phase ions. As the laser hits the matrix, laser energy is 
transformed into excitation energy causing sublimation of the analyte and matrix (Figure 2.5). 
The mass and charges of the analytes are then measured by downstream analysers, described 
in 2.3.3.3. The m/z of each analyte is calibrated either externally, by independent analysis of a 
known sample, or internally by pre-mixing a peptide of known m/z with the sample-matrix 
mixture. The mechanisms by which ions are formed in MALDI are still not fully understood. 
MALDI is often combined with a time-of-flight (ToF) analyser (described in 2.3.3.3.1). 
MALDI-ToF is fast, sensitive and provides high mass resolution. 
 
Figure 2.5 Matrix-assisted laser desorption/ionisation process. The laser beam is focused 
onto matrix-analyte crystal and excites the matrix, causing localised disintegration of the 
crystal. The analytes become ionised and desorped
82
. 
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2.3.3.2.2. Electrospray ionisation 
In ESI
83
, samples are dissolved in a solvent or a buffer, and infused into the 
ionisation source through a narrow capillary (Figure 2.6). High voltage applied to the 
capillary tip creates strong electric field, which generates highly charged sample droplets. 
The size of the sample droplets decreases into smaller highly charged droplets through 
application of a nebulising gas that flows around the capillary. Eventually, the solvent 
vaporises resulting in desolvated ions through application of warm neural gas or a drying gas 
such as nitrogen. The charged sample ions pass through an orifice into the mass spectrometer 
for detection of mass and charge.  
 
 
Figure 2.6 Electrospray ionisation process. The analyte solution is passed through a charged 
capillary. This creates charged sample droplets. Droplets evaporate in the presence of 
nitrogen, and they break down into smaller droplets until the ions are desorped
84
. 
 
ESI is often coupled with liquid chromatography (LC) for online separation of 
proteins, peptides and small molecules
85, 86
. The most commonly used LC types are reversed-
phase LC and hydrophobic interaction LC
87
. Reversed-phase LC uses hydrophobic stationary 
phase and an aqueous polar mobile phase. The most commonly used stationary phase is silica 
linked to alkyl chains. (C4, C5, C8, C18). Analytes captured by the alkyl column are eluted; the 
most hydrophilic analytes elute first. These elutions are injected directly into the ionisation 
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chamber of the mass spectrometer. Recently, nanospray technology was developed
88
, which 
operates at a very low flow rate (nL/min). Compared with the standard ESI, nanospray uses 
far less sample amount so it is ideal for rare or specialised samples. ESI is often used together 
with hybrid quadrupole orthogonal time-of-flight (Q-ToF) mass spectrometer (described in 
2.3.3.3.2).  
2.3.3.3. Mass analysers 
2.3.3.3.1. Time-of-flight mass spectrometry 
ToF mass analyser ion separation methodology is based on the free flight of the ions 
in a 1-2m length tube before reaching the detector. The ToF analyser separates ions according 
to their m/z by noting the time it takes for ions to hit the detector; lighter ions are faster than 
the heavier ones. The first ToF analyser developed was linear (Figure 2.7 A). This model did 
not counter in the fact that ions entering the analyser could have different kinetic energies, 
which compromises resolution and accuracy. In the 1970’s, reflectron was developed89, which 
works as an electrostatic ion mirror. Ions with greater kinetic energy penetrate deeper into the 
reflectron, and are repelled more slowly than ions with lower kinetic energy; thus, ions would 
leave the reflectron at the same time (Figure 2.7 B). Since the differences in kinetic energy 
are mitigated, the mass and charge can be measured accurately. This improved the resolution 
as well as the mass accuracy due to longer tube length and increase in the flight time
90
. 
2.3.3.3.2. Quadrupole time-of-flight mass spectrometry 
In 1996, Morris’s group combined the scanning capabilities of quadrupole and 
resolving power of ToF analyser to create Q-ToF MS (Figure 2.8)
91
. A quadrupole analyser 
has four parallel electrical rods with two linked to direct current potential and the others with 
an alternating radio frequency. Gas-phase ions generated from an ion source undergo 
complex oscillation as the polarity of the rods change and only those within a narrow range of 
m/z passes through the first quadrupole. Those precursor ions chosen to pass through the first 
quadrupole then undergo collision-induced dissociation with an inert gas (e.g. nitrogen) 
within the collision cell, one precursor at a time, which causes them to fragment
92
. They then 
pass through a second quadrupole. The fragmented ions are detected by a ToF mass analyser, 
which measures the m/z of each ion to create the second m/z spectrum that specifically 
reflects the fragment ions generated from only one precursor ion. This type of procedure is 
called tandem mass spectrometry (MS/MS) since there are two rounds of mass spectrometry. 
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Figure 2.7 Schematic diagram of time-of-flight mass analysers: (A) conventional, and (B) 
reflectron-type
93
. 
 
 
Figure 2.8 Schematic diagram of Quadrupole time-of-flight mass spectrometer
82
. 
 
A Q-ToF system provides fast acquisition speed, high resolution, sensitivity and mass 
accuracy. The instrument uses information-dependent acquisition (IDA) mode to record m/z 
of the precursor ion and the fragment ions of each precursor. Hence, the amino acid sequence 
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of the precursor ion can be determined bioinformatically or by de novo sequencing
94
.  
2.3.3.3.3. Triple quadrupole mass spectrometry 
Triple quadrupole mass spectrometer uses three quadrupole mass analysers in series. 
The first quadrupole selects precursor ions of interest followed by collision-induced 
dissociation in the second quadrupole. Third quadrupole can be set to scan the entire m/z 
range of resulting fragment ions (product ion scan) or select fragment ion of interest 
(precursor ion scan).  
2.3.4. Multiple reaction monitoring  
Over the past few decades, multiple reaction monitoring (MRM) has been widely 
used to study small molecules and peptides including metabolites
95
, hormones
96
, 
pharmaceutical compounds and pesticides
97
 in complex mixtures. In recent years, MRM-MS 
has been adapted to quantitatively analyse proteins in complex mixtures such as CSF
98, 99
, 
plasma
100-102
, serum
100, 103
 and tissue
104
. This technique emerged as a useful MS technique for 
verifying and validating biomarkers, and in systems biology
101, 105
 to complement discovery-
based experiments by facilitating hypothesis-driven proteomic analysis.  
MRM uses triple quadrupole MS for targeted quantitative analysis. In an MRM 
analysis, upon ionisation in an electrospray source, the first quadrupole identifies and selects 
peptide ions. Peptide ions are guided into the second quadrupole where it is further 
fragmented into fragment ions, and then the third quadrupole selects the fragment ion of 
interest (Figure 2.9). This peptide/fragment ion m/z pair is called a transition. Initial MRM 
transition optimisation is done in combination with IDA to ensure that the transition truly 
relates to the protein of interest. Then, collision energy (CE) is optimised to determine the 
best settings to achieve maximum selectivity and spectral response. Once optimised, several 
transitions are monitored over time for each protein for quantitative analysis. Background 
ions that may co-elute with the targeted ions are filtered through the two levels of mass 
selection, making this a highly sensitive and selective analysis. This feature allows the 
researchers to target peptides in highly complex biological samples. Also, post-translational 
modification (PTM) and protein isoforms can be studied with MRM upon development of 
transitions unique to the modified/isoform proteins. A number of studies utilised MRM 
analysis to identify and quantify protein isoforms
106
 and PTMs, including phosphorylation
107
, 
ubiquitination
108
 and acetylation
109
. Immunoassays such as Western blotting and ELISA have 
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major disadvantages that are avoided in MRM: (i) some antibodies are limited in availability, 
(ii) de novo development of immunoassays can take months, (iii) commercially available 
antibodies often show strong cross reactivity to non-targeting proteins. In addition, MRM has 
the major advantage over immunoassays because it allows high-throughput multiplexing, 
where up to 100 proteins can be quantified in a single run
110
. Previous studies have 
continuously shown the reproducibility, specificity and sensitivity of the MRM assay for 
quantitative protein analysis
101, 102, 110
. 
 
 
Figure 2.9 Schematic diagram of multiple reaction monitoring experiment
104
. 
 
The MRM assay can be used as label-free approach or in combination with mTRAQ 
labelling. This technique involves labelling of sample extracts with mTRAQ Reagents Δ0 or 
mTRAQ Reagents Δ4, and global internal standard with mTRAQ Reagents Δ8. Like 2D-
DIGE, mTRAQ utilises a global internal standard, a pooled mix of the samples used in the 
analysis, which allows normalisation and comparison across the whole samples, and corrects 
for experimental inconsistencies. The mTRAQ labels are isotopic variants of the same label 
so the retention time on the LC does not change; only the mass units differ by 4 Da.  
2.3.5. SWATH-based mass spectrometry 
Recently, a new technique called sequential window acquisition of all theoretical 
fragment-ion spectra (SWATH) was introduced for targeted protein quantitation to provide 
MRM-like reproducibility but with higher multiplexing. SWATH utilises the unique 
properties of the triple quadrupole MS instrument to perform information-independent 
acquisition (IIA) MS scans of all the peptides in the sample to generate a mass spectrometric 
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reference map of the target proteome
111
, followed by targeted quantitative data analysis
112
. In 
SWATH-based acquisition, the first quadrupole is set to pass m/z of precursor ions at 25 Da 
increments. The transmitted ions are fragmented in the collision cell, and then the fragment 
ions are analysed at high resolution (Figure 2.10). SWATH requires no upfront assay 
development, allows comprehensive quantitative data acquisition for all the analytes in the 
sample and the acquired data can be mined post-acquisition.  
 
 
Figure 2.10 Schematic diagram of SWATH experiment (adopted from
111
). 
 
2.4. Proteomics in Alzheimer’s disease 
Since early 1990s, 2-DE and 2D-DIGE have been widely used for comparative 
proteomics to study changes in protein abundance patterns associated with AD in CSF, 
plasma, serum and brain tissue
59, 113-115
. This section will mainly focus on study of autopsy 
tissue. Mattila and colleagues (1994) used 2-DE to separate proteins from AD frontal cerebral 
cortex, and quantitatively visualised about 800 protein spots using silver staining. They used 
immunoblotting to identify proteins that have commercially available antibodies (actin, 
albumin, glial fibrillary acidic protein, neuron-specific enolase and S-100) in the 2D patterns. 
Three protein spots exhibited significant differences in their spot intensity in AD compared 
with control; however, the identity of these proteins could not be determined due to lack of 
technological advancement in 1994. In the early 2000s, neuroscientists started to combine 2-
DE with MALDI-ToF or ESI-ToF MS to uncover identity of protein spots exhibiting 
significant abundance changes in AD brain tissue
55, 116-121
: NADH dehydrogenase ubiquinone 
75 kDa, dihydropyrimidinase-like protein 2, fatty acid-binding protein heart, glial fibrillary 
acidic protein, peroxiredoxin 2, glyceraldehyde 3-P dehydrogenase, triose phosphate 
isomerase 1 and -tubulin. Molloy’s group (2003) described that the technical variation in 2-
DE is about 20-30%
122
, and the researchers are inevitably required to analyse more replicates 
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and sample cases. This is not ideal when dealing with scarce samples like human brain tissues. 
With introduction of 2D-DIGE, several studies utilised this technique for more reliable 
quantitative analysis of proteins from human
53
 and transgenic animal model
123, 124
, including 
one of our studies, which is described in Chapter 3. The use of internal standard reduces the 
technical variation to 7%
125
.  
Improvements in MS instrument performance lead to gradual shift from gel-based to 
gel-free proteomics. Using LC-MS/MS, more proteins could be identified from the brain 
proteome than before. Witzmann and colleagues (2005) used both 2-DE and LC-MS/MS to 
profile synaptosomal fractions from rat forebrain, which revealed 91 unique proteins with 2-
DE, and additional 155 proteins with LC-MS/MS
126
. Stable isotope labeling methods such as 
iTRAQ generated great interest for relative quantification. Using iTRAQ, a group studying 
human post-mortem tissue identified a total of 548 unique proteins from AD frontal cortex, 
and around 350 proteins could be quantified
127
. They found higher abundance of antioxidant 
proteins, including Cu-Zn superoxide dismutase and serum albumin precursor, and lower 
abundance of mitochondrial electron transport proteins. More recently, Manavalan’s group 
(2013) identified 950 unique proteins in hippocampus, parietal cortex and cerebellum, and 
found significantly altered abundance of proteins involved in synaptic plasticity, molecular 
transport, apoptosis and nervous system development in human AD brain
128
. By reducing the 
sample complexity through membrane protein fractionation, Donovan et al. (2012) identified 
1709 different proteins from human AD and non-AD frontal cortices
129
. Furthermore, several 
studies compared the abundance of proteins with PTMs, including phosphorylation
130
 and 
glycoproteins
131
. 
MRM has become a popular tool for quantitative protein analysis in the past few 
years
132, 133
. Surprisingly, only nine papers have been published in the field of 
neuroproteomics to study neurodegenerative disorders using MRM
99, 104, 134-140
. Bethena’s 
group (2012) developed a sensitive MRM-based LC-MS/MS method to quantify myo-insitol 
in mouse brain
140
. Hydrophilic interaction LC was used to improve retention of hydrophilic 
analyte that co-eluted with other endogenous compounds in the biological matrix in reverse-
phase LC. Hydrophilic interaction LC, in combination with optimised chromatographic 
conditions leads to sensitive and reproducible method development. This method can easily 
be applied for quantitative study of amino acids that function as excitatory neurotransmitters 
in the brain, which may help in understanding the aetiology and progression of 
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neurodegenerative disorders. Other studies used MRM to quantitatively target clustering 
abundance patterns in serum
134
 and brain
136
, glycoproteins
137
, a Chinese herb ingredient with 
potential for treatment of neurodegenerative disease
99
, ubiquitin carboxyl-terminal hydrolase 
L1
138
, apolipoprotein E
139
 and several synaptic proteins
104
. Much of the interest in proteomics 
has been in comparing protein abundance from diseased and healthy brain tissues. With the 
introduction of stable isotope tracers and its incorporation into MS, protein turnover analysis 
became possible in cells and whole organisms. Basak and colleagues (2012) developed a 
stable isotope pulse labelling kinetics technique that can assess protein dynamics in the 
brain
135
. With MRM, they measured the clearance of A levels from the mouse brain in vivo. 
Study of protein dynamics is a fundamental step to go deeper in our understanding of process 
involved in neurodegeneration. 
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2.5. Thesis aims and objectives 
Synaptic dysfunction and degeneration is a primary pathology for AD, and 
contributes to clinical dementia. Although the degree of synaptic loss best correlates with 
cognitive decline in AD, the molecular mechanisms underlying synaptic loss remains largely 
unknown. Identifying abnormally expressed synaptic proteins will help elucidate those 
mechanisms. 
The overall aim of the studies presented in this thesis was to compare the synaptic 
proteome in AD-affected areas with relatively spared areas of human brain by using 
comparative proteomics-based techniques. The working hypothesis was that synaptic proteins 
present in human AD brain are different from those in normal ageing brain. In addition, I 
expected that proteomic analysis of the synaptic proteome from AD brain would reveal new 
protein changes that are related to AD pathogenesis. 
The specific aims of this study were: 
 To prepare synaptic protein fractions from diseased (AD) and control human brain 
tissues 
 To use 2D-DIGE to assess the levels of synaptosomal proteins in AD by comparing 
severely affected and relatively spared areas of the brain in each disease state 
 To identify AD-altered synaptic proteins using MALDI- ToF MS, ESI-QToF MS and 
online database searching 
 To verify that the differences observed in protein levels and identities using 2D-
DIGE and MS (MALDI-ToF and ESI-QToF) are accurate by using label-free 
multiple reaction monitoring 
 To gain a greater understanding of synaptic proteome in AD brain by using strong 
cation exchange separation prior to SWATH analysis 
 
 
 
P a g e | 27 
2.6. References 
1. Hebert, L.E., Scherr, P.A., Bienias, J.L., Bennett, D.A. & Evans, D.A. Alzheimer 
disease in the US population: prevalence estimates using the 2000 census. Arch. Neurol. 60, 
1119-1122 (2003). 
2. Australian Institute of Health and Welfare. Dementia in Australia. (2012). 
3. Alzheimer's Australia. Pfizer Health Report Issue #45 - Dementia. (2011). 
4. Access Economics. Keeping Dementia Front of Mind: Incidence and prevalence 
2009-2050. (2009). 
5. Terry, R.D. & Katzman, R. Senile dementia of the Alzheimer type. Ann. Neurol. 14, 
497-506 (1983). 
6. Mercy, L., Hodges, J.R., Dawson, K., Barker, R.A. & Brayne, C. Incidence of early-
onset dementias in Cambridgeshire, United Kingdom. Neurology 71, 1496-1499 (2008). 
7. Brookmeyer, R., Gray, S. & Kawas, C. Projections of Alzheimer's disease in the 
United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 
1337-1342 (1998). 
8. DeKosky, S.T. & Marek, K. Looking backward to move forward: early detection of 
neurodegenerative disorders. Science 302, 830-834 (2003). 
9. Walsh, J.S., Welch, H.G. & Larson, E.B. Survival of outpatients with Alzheimer-type 
dementia. Ann. Intern. Med. 113, 429-434 (1990). 
10. Connell, C.M., Janevic, M.R. & Gallant, M.P. The costs of caring: impact of 
dementia on family caregivers. J. Geriatr. Psychiatry Neurol. 14, 179-187 (2001). 
11. McKhann, G., et al. Clinical diagnosis of Alzheimer's disease: report of the 
NINCDS-ADRDA Work Group under the auspices of Department of Health and Human 
Services Task Force on Alzheimer's Disease. Neurology 34, 939-944 (1984). 
12. Alzheimer's Australia. Alzheimer's disease. (2014). 
13. O'Connor, D.W., et al. Do general practitioners miss dementia in elderly patients? 
14. Mirra, S.S., et al. The Consortium to Establish a Registry for Alzheimer's Disease 
(CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. 
Neurology 41, 479-486 (1991). 
P a g e | 28 
15. Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. 
Acta Neuropathol. (Berl). 82, 239-259 (1991). 
16. The National Institute on Aging and Reagan Institute Working Group on Diagnostic 
Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus 
Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease. Neurobiol. Aging 
18, S1-S2 (1997). 
17. Murayama, S. & Saito, Y. Neuropathological diagnostic criteria for Alzheimer's 
disease. Neuropathology 24, 254-260 (2004). 
18. Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress 
and problems on the road to therapeutics. Science 297, 353-356 (2002). 
19. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-
766 (2001). 
20. Gunawardena, S. & Goldstein, L.S. Disruption of axonal transport and neuronal 
viability by amyloid precursor protein mutations in Drosophila. Neuron 32, 389-401 (2001). 
21. Dawson, G.R., et al. Age-related cognitive deficits, impaired long-term potentiation 
and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. 
Neuroscience 90, 1-13 (1999). 
22. Loffler, J. & Huber, G. β-amyloid precursor protein informs in various rat brain 
regions and during development. J. Neurochem. 59, 1316-1324 (1992). 
23. Bird, T.D. Genetic aspects of Alzheimer disease. Genet. Med. 10, 231-239 (2008). 
24. Kosik, K.S., Crandall, J.E., Mufson, E.J. & Neve, R.L. Tau in situ hybridization in 
normal and Alzheimer brain: localization in the somatodendritic compartment. Ann. Neurol. 
26, 352-361 (1989). 
25. Grundke-Iqbal, I., et al. Abnormal phosphorylation of the microtubule-associated 
protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83, 
4913-4917 (1986). 
26. Callahan, L.M. & Coleman, P.D. Neurons bearing neurofibrillary tangples are 
responsible for selected synaptic deficits in Alzheimer's disease. Neurobiol. Aging 16, 311-
314 (1995). 
27. Callahan, L.M., Vaules, W.A. & Coleman, P.D. Quantitative decrease in 
P a g e | 29 
synaptophysin message expression and increase in cathepsin D message expression in 
Alzheimer disease neurons containing neurofibrillary tangles. J. Neuropathol. Exp. Neurol. 
58, 275-287 (1999). 
28. Callahan, L.M., Vaules, W.A. & Coleman, P.D. Progressive reduction of 
synaptophysin message in single neurons in Alzheimer disease. J. Neuropathol. Exp. Neurol. 
61, 384-395 (2002). 
29. Terry, R.D., et al. Physical basis of cognitive alterations in Alzheimer's disease: 
synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991). 
30. DeKosky, S.T. & Scheff, S.W. Synapse loss in frontal cortex biopsies in Alzheimer's 
disease: correlation with cognitive severity. Ann. Neurol. 27, 457-464 (1990). 
31. Sze, C.I., Bi, H., Kleinschmidt-DeMasters, B.K., Filley, C.N. & Martin, L.J. 
Selective regional loss of exocytotic presynaptic vesicle proteins in Alzheimer's diease brains. 
J. Neurol. Sci. 175, 81-90 (2000). 
32. Blennow, K., Bogdanovic, N., Alafuzoff, I., Ekman, R. & Davidsson, P. Synaptic 
pathology in Alzheimer's dosease: relation to severity of dementia, but not to senile plaques, 
neurobifrillary tangles, or the ApoE4 allele. J. Neural Transm. 103, 603-618 (1996). 
33. Honer, W.G., Dickson, D.W., Gleeson, J. & Davies, P. Regional synaptic pathology 
in Alzheimer's disease. Neurobiol. Aging 13, 375-382 (1992). 
34. Davis, C.A., Mann, D., M, Sumpter, P.A. & Yates, P.O. A quantitative morphometric 
analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients 
with Alzheimer's disease. J. Neurol. Sci. 78, 151-164 (1987). 
35. DeKosky, S.T., Scheff, S.W. & Styren, S.D. Structural correlates of cognition in 
dementia: quantification and assessment of synapse change. Neurodegeneration 5, 417-421 
(1996). 
36. Buell, S.J. & Coleman, P.D. Dendritiv growth in the aged human brain failure of 
growth in senile dementia. Science 206, 854-856 (1979). 
37. Coleman, P.D. & Yao, P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. 
Aging 24, 1023-1027 (2003). 
38. Yao, P.J., et al. Defects in expression of genes related to synaptic vesicle trafficking 
in frontal cortex of Alzheimer's disease. Neurobiol. Dis. 12, 97-109 (2003). 
P a g e | 30 
39. Shankar, G.M. & Walsh, D.M. Alzheimer's disease: synaptic dysfunction and Ab. 
Mol. Neurodegener. 4, 48 (2009). 
40. Kennedy, M.B. The postsynaptic density. Curr. Opin. Neurobiol. 3, 732-737 (1993). 
41. Bai, F. & Witzmann, F.A. Synaptosome proteomics. Subcell. Biochem. 43, 77-98 
(2007). 
42. Yuste, R. & Bonhoeffer, T. Morphological changes in dendritic spines associated 
with long-term synaptic plasticity. Annu. Rev. Neurosci. 24, 1071-1089 (2001). 
43. Coleman, P.D., Federoff, H. & Kurlan, R. A focus on the synapse for neuroprotection 
and other dementias. Neurology 63, 1155-1162 (2004). 
44. Whittaker, V.P., Michaelson, I.A. & Kirkland, R.J. The separation of synaptic 
vesicles from nerve-ending particles ('synaptosomes'). Biochem. J. 90, 293-303 (1964). 
45. Hebb, C.O. & Whittaker, V.P. Intracellular distributions of acetylcholine and choline 
acetylase. J. Physiol, 142, 187-196 (1958). 
46. Schrimpf, S.P., et al. Proteomic analysis of synaptosomes using isotope-coded 
affinity tags and mass spectrometry. Proteomics 5, 2531-2541 (2005). 
47. Dodd, P.R., et al. Optimization of freezing, storage, and thawing conditions for the 
preparation of metabolically active synaptosomes from frozen rat and human brain. 
Neurochem. Pathol. 4, 177-198 (1986). 
48. Hardy, J.A., et al. Amino acid transport by synaptosomes isolated from post mortem 
human brain. J. Neural Transm. 60, 57-62 (1984). 
49. Hardy, J.A., et al. Uptake of gamma-aminobutyric acid and glycine by synaptosomes 
from postmortem human brain. J. Neurochem. 47, 460-467 (1986). 
50. Daniel, J.A., Malladi, C.S., Kettle, E., McCluskey, A. & Robinson, P.J. Analysis of 
synaptic vesicle endocytosis in synaptosomes by high-content screening. Nat. Protoc. 7, 
1439-1455 (2012). 
51. Iwangoff, P., Armbruster, R., Enz, A. & Meier-Ruge, W. Glycolytic enzymes from 
human autoptic brain cortex: normal aged and demented cases. Mech. Ageing Dev. 14, 203-
209 (1980). 
52. Dumont, D., Noben, J.P., Verhaert, P., Stinissen, P. & Robben, J. Gel-free analysis of 
the human brain proteome: application of liquid chromatography and mass spectrometry on 
P a g e | 31 
biopsy and autopsy samples. Proteomics 6, 4967-4977 (2006). 
53. Chang, R.Y.K., Nouwens, A.S., Dodd, P.R. & Etheridge, N. The synaptic proteome in 
Alzheimer's disease. Alzheimers Dement. 9, 499-511 (2013). 
54. Etheridge, N., Lewohl, J.M., Mayfield, R.D., Harris, R.A. & Dodd, P.R. Synaptic 
proteome changes in the superior frontal gyrus and occipital cortex of the alcoholic brain. 
Proteomics Clin. Appl. 3, 730-742 (2009). 
55. Sultana, R., et al. Proteomics analysis of the Alzheimer's disease hippocampal 
proteome. J. Alzheimer's Dis. 11, 153-164 (2007). 
56. Reumer, A., et al. Colorectal cancer biomarker discovery and validation using LC-
MS/MS-based proteomics in blood: truth or dare? Expert. Rev. Proteomics  (2014). 
57. van Bon, L., et al. Proteomic analysis of plasma identifies the Toll-like receptor 
agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann. 
Rheum. Dis.  (2014). 
58. Xu, X.R., et al. Comparative proteomic analysis of plasma proteins in patients with 
age-related macular degeneration. Int. J. Ophthalmol. 7, 256-263 (2014). 
59. Alafuzoff, I., et al. Isoelectric focusing and two-dimensional gel electrophoresis in 
plasma and cerebrospinal fluid from patients with dementia. Eur. Neurol. 25, 285-289 (1986). 
60. Koutroukides, T.A., et al. Identification of protein biomarkers in human serum using 
iTRAQ and shotgun mass spectrometry. Methods Mol. Biol. 1061, 291-307 (2013). 
61. Miller, M., et al. The Serum Proteome of Non-Alcoholic Fatty Liver Disease - A 
multimodal approach to discovery of biomarkers of Non-Alcoholic Steatohepatitis. J. 
Gastroenterol. Hepatol.  (2014). 
62. Rath, T., et al. Serum proteome profiling identifies novel and powerful markers of 
cystic fibrosis liver disease. PLoS One 8, e58955 (2013). 
63. Ijsselstijn, L., et al. Comparative Study of Targeted and Label-free Mass 
Spectrometry Methods for Protein Quantification. J. Proteome Res.  (2013). 
64. von Neuhoff, N., et al. Monitoring CSF proteome alterations in amyotrophic lateral 
sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic. PLoS 
One 7, e44401 (2012). 
65. Lehnert, S., et al. iTRAQ and multiple reaction monitoring as proteomic tools for 
P a g e | 32 
biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Exp. 
Neurol. 234, 499-505 (2012). 
66. Goda, R. & Kobayashi, N. Evaluation of peptide adsorption-controlled liquid 
chromatography-tandem mass spectrometric (PAC-LC-MS/MS) method for simple and 
simultaneous quantitation of amyloid beta 1-38, 1-40, 1-42 and 1-43 peptides in dog 
cerebrospinal fluid. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 895-896, 137-145 
(2012). 
67. Lame, M.E., Chambers, E.E. & Blatnik, M. Quantitation of amyloid beta peptides 
Abeta(1-38), Abeta(1-40), and Abeta(1-42) in human cerebrospinal fluid by ultra-
performance liquid chromatography-tandem mass spectrometry. Anal. Biochem. 419, 133-139 
(2011). 
68. Kim, S.I., et al. Neuroproteomics: expression profiling of the brain's proteomes in 
health and disease. Neurochem. Res. 29, 1317-1331 (2004). 
69. Rabilloud, T. Two-dimensional gel electrophoresis in proteomics: old, old fashioned, 
but it still climbs up the mountains. Proteomics Clin. Appl. 2, 3-10 (2002). 
70. Raymond, S. & Weintraub, L. Acrylamide gel as a supporting medium for zone 
electrophoresis. Science 130, 711 (1959). 
71. Dale, G. & Latner, A.L. Isoelectric focusing of serum proteins in acrylamide gels 
followed by electrophoresis. Clin. Chim. Acta 24, 61-68 (1969). 
72. Vesterberg, O. & Svensson, H. Isoelectric fractionation, analysis, and 
characterization of ampholytes in natural pH gradients. IV. Further studies on the resolving 
power in connection with separation of myoglobins. Acta Chem. Scand. 20, 820-834 (1966). 
73. Klose, J. Protein mapping by combined isoelectric focusing and electrophoresis of 
mouse tissues. A novel approach to testing for induced point mutations in mammals. 
Humangenetik 26, 231-243 (1975). 
74. O'Farrell, P.H. High resolution two-dimensional electrophoresis of proteins. J. Biol. 
Chem. 250, 4007-4021 (1975). 
75. Bjellqvist, B., et al. Isoelectric focusing in immobilized pH gradients: principle, 
methodology and some applications. J. Biochem. Biophys. Methods 6, 317-339 (1982). 
76. Zetterberg, H., et al. Clinical proteomics in neurodegenerative disorders. Acta Neurol. 
P a g e | 33 
Scand. 118, 1-11 (2008). 
77. Butterfield, D.A., Perluigi, M. & Sultana, R. Oxidative stress in Alzheimer's disease 
brain: New insights from redox proteomics. Eur. J. Pharmacol. 545, 39-50 (2006). 
78. Hortin, G.L. Proteomics: a new diagnostic frontier. Clin. Chem. 52, 1223-1237 
(2006). 
79. Fenn, J.B., Mann, M., Meng, C.K., Wond, S.F. & Witehouse, C.M. Electrospray 
ionization for mass spectrometry of large biomolecules. Science 246, 64-71 (1989). 
80. Tanaka, K., et al. Protein and polymer analyses up to m/z 100 000 by laser ionization 
time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom. 2, 151-153 (1988). 
81. Karas, M. & Hillenkamp, F. Laser desorption ionization of proteins with molecular 
masses exceeding 10,000 daltons. Anal. Chem. 60, 2299-2301 (1988). 
82. El-Aneed, A., Cohen, A. & Banoub, J. Mass spectrometry, review of the basics: 
Electrospray, MALDI, and commonly used mass analyzers. Appl. Spectrosc. Rev. 44, 210-230 
(2009). 
83. Fenn, J.B., Mann, M., Meng, C.K., Wong, S.F. & Whitehouse, C.M. Electrospray 
ionization for mass spectrometry of large biomolecules. Science 246, 64-71 (1989). 
84. Hendrickson. Electrospray Ionization. (National High Magnetic Field Laboratory, 
Tallahassee, 2014). 
85. Cohen, A.M., Mansour, A.A. & Banoub, J.H. Absolute quantification of Atlantic 
salmon and rainbow trour vitellopgenin by the "signature peptide" approach using 
electrospray ionization QqToF tandem mass spectrometry. J. Mass Spectrom. 41, 646-658 
(2006). 
86. Whitehouse, C.M., Dreyer, R.N., Yamashita, M. & Fenn, J.B. Electrospray interface 
for liquid chromatographs and mass spectrometers. Anal. Chem. 57, 675-679 (1985). 
87. Capriotti, A.L., Cavaliere, C., Foglia, P., Samperi, R. & Lagana, A. Intact protein 
separation by chromatographic and/or electrophoretic techniques for top-down proteomics. J. 
Chromatogr. A 1218, 8760-8776 (2011). 
88. Wilm, M. & Mann, M. Analytical properties of the nanoelectrospray ion source. Anal. 
Chem. 68, 1-8 (1996). 
89. Mamyrin, B.A. & Shmikk, D.V. The linear mass reflectron. Sov. Phys. JETP 49, 762-
P a g e | 34 
764 (1979). 
90. Clauser, K.R., Baker, P. & Burlingame, A.L. Role of accurate mass measurement (+/- 
10 ppm) in protein identification strategies employing MS or MS/MS and database searching. 
Anal. Chem. 71, 2871-2882 (1999). 
91. Morris, H.R., et al. High sensitivity collisionally-activated decomposition tandem 
mass spectrometry on a novel quadrupole/orthogonal-acceleration time-of-flight mass 
spectrometer. Rapid Commun. Mass Spectrom. 10, 889-896 (1996). 
92. Jennings, K.R. Collision-induced decompositions of aromatic molecular ions. Int. J. 
Mass Spectrom. Ion Phys. 1, 227-235 (1968). 
93. Annan, R.S. Phosphopeptide analysis by MALDI-ToF mass spectrometry. (The 
Association of Biomolecular Resource Facilities, SmithKline Beecham Pharmaceuricals, 
1999). 
94. El-Aneed, A., Cohen, A.M. & Banoub, J.H. Mass spectrometry, review of the basics: 
electrospray, MALDI, and commonly used mass analyzers. Appl. Spectrosc. Rev. 44, 210-230 
(2009). 
95. Zhang, N., Fountain, S.T., Bi, H. & Rossi, D.T. Quantification and rapid metabolite 
identification in drug discovery using API time-of-flight LC/MS. Anal. Chem. 72, 800-806 
(2000). 
96. Tai, S.S., Bunk, D.M., White, E.t. & Welch, M.J. Development and evaluation of a 
reference measurement procedure for the determination of total 3,3',5-triiodothyronine in 
human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal. 
Chem. 76, 5092-5096 (2004). 
97. Sannino, A., Bolzoni, L. & Bandini, M. Application of liquid chromatography with 
electrospray tandem mass spectrometry to the determination of a new generation of pesticides 
in processed fruits and vegetables. J. Chromatogr. A 1036, 161-169 (2004). 
98. Bora, A., Anderson, C., Bachani, M., Nath, A. & Cotter, R.J. Robust Two-
Dimensional Separation of Intact Proteins for Bottom-Up Tandem Mass Spectrometry of the 
Human CSF Proteome. J. Proteome Res.  (2012). 
99. Wang, Q., et al. HPLC-APCI-MS/MS method for the determination of catalpol in rat 
plasma and cerebrospinal fluid: Application to an in vivo pharmacokinetic study. J. Pharm. 
Biomed. Anal.  (2012). 
P a g e | 35 
100. Kuhn, E., et al. Quantification of C-reactive protein in the serum of patients with 
rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C-labeled 
peptide standards. Proteomics 4, 1175-1186 (2004). 
101. Anderson, L. & Hunter, C.L. Quantitative mass spectrometric multiple reaction 
monitoring assays for major plasma proteins. Mol. Cell. Proteomics 5, 573-588 (2006). 
102. Addona, T.A., et al. Multi-site assessment of the precision and reproducibility of 
multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27, 
633-641 (2009). 
103. Barnidge, D.R., Goodmanson, M.K., Klee, G.G. & Muddiman, D.C. Absolute 
quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS 
using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 3, 644-652 
(2004). 
104. Chang, R.Y.K., Etheridge, N., Dodd, P.R. & Nouwens, A.S. Quantitative multiple 
reaction monitoring analysis of synaptic proteins from human brain. J. Neurosci. Methods 
227, 189-210 (2014). 
105. Shi, T., et al. Advancing the sensitivity of selected reaction monitoring-based 
targeted quantitative proteomics. Proteomics 12, 1074-1092 (2012). 
106. Wang, Q., et al. Mutant proteins as cancer-specific biomarkers. Proc. Natl. Acad. Sci. 
U. S. A. 108, 2444-2449 (2011). 
107. Unwin, R.D., et al. Multiple reaction monitoring to identify sites of protein 
phosphorylation with high sensitivity. Mol. Cell. Proteomics 4, 1134-1144 (2005). 
108. Mollah, S., et al. Targeted mass spectrometric strategy for global mapping of 
ubiquitination on proteins. Rapid Commun. Mass Spectrom. 21, 3357-3364 (2007). 
109. Griffiths, J.R., et al. The application of a hypothesis-driven strategy to the sensitive 
detection and location of acetylated lysine residues. J. Am. Soc. Mass. Spectrom. 18, 1423-
1428 (2007). 
110. Picotti, P., Bodenmiller, B., Mueller, L.N., Domon, B. & Aebersold, R. Full dynamic 
range proteome analysis of S. cerevisiae by targeted proteomics. Cell 138, 795-806 (2009). 
111. Liu, Y., Huttenhain, R., Collins, B. & Aebersold, R. Mass spectrometric protein maps 
for biomarker discovery and clinical research. Expert Rev. Mol. Diagn. 13, 811-825 (2013). 
P a g e | 36 
112. Gillet, L.C., et al. Targeted data extraction of the MS/MS spectra generated by data-
independent acquisition: a new concept for consistent and accurate proteome analysis. Mol. 
Cell. Proteomics 11, O111 016717 (2012). 
113. Mattila, K.M. & Frey, H. Two-dimensional analysis of qualitative and quantitative 
changes in blood cell proteins in Alzheimer's disease: search for extraneuronal markers. Appl. 
Theor. Electrophor. 4, 189-196 (1995). 
114. Mattila, K.M. & Frey, H. Alzheimer brain proteins investigated by two-dimensional 
gel electrophoresis with immobilized pH gradients in the first dimension. Electrophoresis 15, 
721-725 (1994). 
115. Ai, K.Z., Vermuyten, K., De Deyn, P.P., Lowenthal, A. & Karcher, D. A serum 
protein involved in aging? Mol. Chem. Neuropathol. 11, 131-141 (1989). 
116. Kim, S.H., Vlkolinsky, R., Cairns, N., Fountoulakis, M. & Lubec, G. The reduction 
of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with 
Down syndrome and Alzheimer's disease. Life Sci. 68, 2741-2750 (2001). 
117. Schonberger, S.J., Edgar, P.F., Kydd, R., Faull, R.L. & Cooper, G.J. Proteomic 
analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease 
process. Proteomics 1, 1519-1528 (2001). 
118. Tsuji, T., Shiozaki, A., Kohno, R., Yoshizato, K. & Shimohama, S. Proteomic 
profiling and neurodegeneration in Alzheimer's disease. Neurochem. Res. 27, 1245-1253 
(2002). 
119. Cheon, M.S., Kim, S.H., Fountoulakis, M. & Lubec, G. Heart type fatty acid binding 
protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer's 
disease. J. Neural Transm. Suppl., 225-234 (2003). 
120. Krapfenbauer, K., Engidawork, E., Cairns, N., Fountoulakis, M. & Lubec, G. 
Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 
967, 152-160 (2003). 
121. Shiozaki, A., et al. Proteome analysis of brain proteins in Alzheimer's disease: 
subproteomics following sequentially extracted protein preparation. J. Alzheimer's Dis. 6, 
257-268 (2004). 
122. Molloy, M.P., Brzezinski, E.E., Hang, J., McDowell, M.T. & VanBogelen, R.A. 
Overcoming technical variation and biological variation in quantitative proteomics. 
P a g e | 37 
Proteomics 3, 1912-1919 (2003). 
123. Sizova, D., et al. Proteomic analysis of brain tissue from an Alzheimer's disease 
mouse model by two-dimensional difference gel electrophoresis. Neurobiol. Aging 28, 357-
370 (2007). 
124. Takano, M., et al. Proteomic analysis of the hippocampus in Alzheimer's disease 
model mice by using two-dimensional fluorescence difference in gel electrophoresis. 
Neurosci. Lett. 534, 85-89 (2013). 
125. Winkler, W., et al. Biological variation of the platelet proteome in the elderly 
population and its implication for biomarker research. Mol. Cell. Proteomics 7, 193-203 
(2008). 
126. Witzmann, F.A., et al. A proteomic survey of rat cerebral cortical synaptosomes. 
Proteomics 5, 2177-2201 (2005). 
127. Melanson, J.E., Avery, S.L. & Pinto, D.M. High-coverage quantitative proteomics 
using amine-specific isotopic labeling. Proteomics 6, 4466-4474 (2006). 
128. Manavalan, A., et al. Brain site-specific proteome changes in aging-related dementia. 
Exp. Mol. Med. 45, e39 (2013). 
129. Donovan, L.E., et al. Analysis of a membrane-enriched proteome from postmortem 
human brain tissue in Alzheimer's disease. Proteomics Clin. Appl. 6, 201-211 (2012). 
130. Hoos, M.D., et al. Longitudinal study of differential protein expression in an 
Alzheimer's mouse model lacking inducible nitric oxide synthase. J. Proteome Res. 12, 4462-
4477 (2013). 
131. Shi, M., Hwang, H. & Zhang, J. Quantitative characterization of glycoproteins in 
neurodegenerative disorders using iTRAQ. Methods Mol. Biol. 951, 279-296 (2013). 
132. Ackermann, B.L. & Berna, M.J. Coupling immunoaffinity techniques with MS for 
quantitative analysis of low-abundance protein biomarkers. Expert. Rev. Proteomics 4, 175-
186 (2007). 
133. Wolf-Yadlin, A., Hautaniemi, S., Lauffenburger, D.A. & White, F.M. Multiple 
reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. 
Proc. Natl. Acad. Sci. U. S. A. 104, 5860-5865 (2007). 
134. L, I.J., et al. Serum clusterin levels are not increased in presymptomatic Alzheimer's 
P a g e | 38 
disease. J. Proteome Res. 10, 2006-2010 (2011). 
135. Basak, J.M., et al. Measurement of apolipoprotein E and amyloid beta clearance rates 
in the mouse brain using bolus stable isotope labeling. Mol. Neurodegener. 7, 14 (2012). 
136. Chen, J., Wang, M. & Turko, I.V. Mass spectrometry quantification of clusterin in the 
human brain. Mol. Neurodegener. 7, 41 (2012). 
137. Stella, R., et al. Relative quantification of membrane proteins in wild-type and prion 
protein (PrP)-knockout cerebellar granule neurons. J. Proteome Res. 11, 523-536 (2012). 
138. Chen, J., Huang, R.Y. & Turko, I.V. Mass spectrometry assessment of ubiquitin 
carboxyl-terminal hydrolase L1 partitioning between soluble and particulate brain 
homogenate fractions. Anal. Chem. 85, 6011-6017 (2013). 
139. Wang, M. & Turko, I.V. Mass spectrometry quantification revealed accumulation of 
C-terminal fragment of apolipoprotein E in the Alzheimer's frontal cortex. PLoS One 8, 
e61498 (2013). 
140. Bathena, S.P., et al. Rapid and reliable quantitation of amino acids and myo-inositol 
in mouse brain by high performance liquid chromatography and tandem mass spectrometry. J. 
Chromatogr. B Analyt. Technol. Biomed. Life Sci. 893-894, 15-20 (2012). 
 
 
  
 
 
 
 
Chapter 3 
Analysis of Synaptic Proteome Using  
Two-dimensional Gel Separation and Fluorescent Label 
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3.1. Introduction 
Two-dimensional differential in-gel electrophoresis (2D-DIGE) is a form of protein separation 
which is used to detect differences in protein expression between diseased and control tissues. 
Synaptosomal fractions isolated from AD and non-AD brain tissues were quantitatively analysed 
with 2D-DIGE. Synaptic proteins that are significantly altered in pathologically susceptible areas 
were identified using MALDI-TOF, ESI-QToF mass spectrometry and online database. 
 
3.2 Declaration of Authorship 
In accordance with the University of Queensland guidelines for thesis partly comprised of 
publications, the background, methods, results, discussion and conclusions of this chapter are 
presented in the form of a manuscript published on Alzheimer’s and Dementia. The contributions of 
all authors are stated at the beginning of the thesis. 
 
3.3. Published paper 
Chang, R. Y. K., Nouwens, A. S., Dodd, P. R., & Etheridge, N. (2013). The synaptic proteome in 
Alzheimer's disease. Alzheimers Dement, 9(5), 499-511.  
 
 
 
 
 
 
 
NOTE: As is common in many publications, throughout this paper I used the term "expression" to denote the 
amount of each protein in the sample. It should be understood that this is meant to imply the abundance or 
concentration of the protein, i.e., the net amount (per mg of total protein) resulting from the excess of 
expression over degradation of that protein. 
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3.4. Supplementary figure legends 
Supplementary Figure 1. Representative gels from all four brain regions of AD and control cases. 
a) Alzheimer’s disease sample hippocampus, b) control sample hippocampus, c) Alzheimer’s 
disease temporal cortex, d) control sample temporal cortex, e) Alzheimer’s disease sample occipital 
cortex, f) control sample occipital cortex, g) Alzheimer’s disease motor cortex, and h) control motor 
cortex. Two-dimensional electrophoretic separation of synaptosomal proteins. The first dimension is 
pH 3–11 non- linear gradients (17cm) and the second dimension is a 10% PAGE. Samples were 
labelled with CyDye and scanned with Typhoon scanner. 
 
Supplementary Figure 2. Two-dimensional electrophoretic separation of synaptosomal proteins. 
The first dimension is pH 3–11 non- linear gradients (17cm) and the second dimension is a 10% 
PAGE. Samples were labelled with CyDye and scanned with Typhoon scanner. Samples with the 
highest and lowest PMI were selected for AD and control cases: a) Alzheimer’s disease sample with 
highest PMI (occipital cortex), b) Alzheimer’s disease sample with lowest PMI (occipital cortex), c) 
control sample with highest PMI (hippocampus), and d) control sample lowest PMI (hippocampus). 
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3.5. Supplementary figures 
Supplementary figure 1. 
a. Alzheimer’s disease sample: Hippocampus 
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b. Control sample: Hippocampus 
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c. Alzheimer’s disease sample: Temporal cortex 
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d. Control sample: Temporal cortex 
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e. Alzheimer’s disease sample: Occipital cortex 
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f. Control sample: Occipital cortex 
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g. Alzheimer’s disease sample: Motor cortex 
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h. Control sample: Motor cortex 
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Supplementary figure 2. 
a. Alzheimer’s disease sample with highest PMI (Occipital cortex) 
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b. Alzheimer’s disease with lowest PMI (Occipital cortex) 
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c. Control sample with highest PMI (Hippocampus) 
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d. Control sample with lowest PMI (Hippocampus) 
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3.6. Supplementary Tables 
 
Supplementary Table1. Case information. PMI, post-mortem interval. Average (Av.) values are 
Means ± S.D. 
Sex Age (y) PMI (h) 
Brain 
Weight (g) 
Cause of death 
Normal subjects 
F 71.10 7.75 1204 Sudden cardiac death 
F 75.78 48.75 1210 Pneumonia 
F 87.38 27.0 1398 Not determined 
F 69.97 23.0 1166 Hypostatic Pneumonia 
F 83.65 26.0 1157 Pulmonary Embolus 
F 77.57 18.0 1272 Respiratory arrest 
Av. 77.6 ± 6.9 25.1 ± 13.6 1235 ± 90  
AD cases 
F 84.79 35.58 1187 Dementia 
F 82.06 41.25 1100 Not determined 
F 78.51 7.5 990 Alzheimer’s disease 
F 89.51 19.5 1040 Not determined 
F 71.33 27.0 1140 Not determined 
F 90.18 20.5 1097 Pneumonia, septicæ mia 
Av. 82.7 ± 7.1 25.2 ± 12.1 1092 ± 70  
 
 
 
 
  
 
 
 
 
Chapter 4 
Method Development –  
Quantitative Multiple Reaction Monitoring Analysis of 
Synaptic Proteins from Human Brain 
 
 
 
 
 
 
 
 
 
 
 
P a g e  | 68 
4.1. Introduction 
Multiple reaction monitoring can specifically target multiples of protein of interests. It is a very 
powerful and sensitive MS technique suitable for quantitative analysis. To target and validate the 
results from 2D-DIGE analysis, MRM method development was necessary. 
 
4.2. Declaration of Authorship 
In accordance with the University of Queensland guidelines for thesis partly comprised of 
publications, the background, methods, results, discussion and conclusions of this chapter are 
presented in the form of a manuscript published on Journal of neuroscience methods. The 
contributions of all authors are stated at the beginning of the thesis. 
 
4.3. Published paper 
Chang, R. Y. K., Etheridge, N., Dodd, P. R., & Nouwens, A. S. (2014). Quantitative multiple 
reaction monitoring analysis of synaptic proteins from human brain. J Neurosci Methods, 227, 189-
210.  
 
 
 
 
 
 
 
 
NOTE: As is common in many publications, throughout this paper I used the term "expression" to denote the 
amount of each protein in the sample. It should be understood that this is meant to imply the abundance or 
concentration of the protein, i.e., the net amount (per mg of total protein) resulting from the excess of 
expression over degradation of that protein. 
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Chapter 5 
Targeted quantitative analysis of synaptic proteins in 
Alzheimer’s disease brain 
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5.1. Introduction 
In Chapter 4, label-free MRM assay was developed for accurate and reproducible quantification of 
synaptic proteins in human brain tissue. Using the MRM assay developed, proteins that were found 
to be differentially regulated in AD-affected areas (2D-DIGE analysis; Chapter 3) were targeted. 
Ten proteins were selected; these were proteins closely associated with AD-related proteins, had not 
been quantified previously, or showed conflicting results in earlier studies. 
 
5.2. Declaration of Authorship 
In accordance with the University of Queensland guidelines for thesis partly comprised of 
publications, the background, methods, results, discussion and conclusions of this chapter are 
presented in the form of a manuscript published on Neurochemistry International. The contributions 
of all authors are stated at the beginning of the thesis. 
 
5.3. Published paper 
Chang, R. Y. K., Etheridge, N., Dodd, P. R., & Nouwens, A. S. (2014). Targeted quantitative 
analysis of synaptic proteins in Alzheimer’s disease brain. Neurochem Int., 75, 66-75. 
 
 
 
 
 
 
 
 
NOTE: As is common in many publications, throughout this paper I used the term "expression" to denote the 
amount of each protein in the sample. It should be understood that this is meant to imply the abundance or 
concentration of the protein, i.e., the net amount (per mg of total protein) resulting from the excess of 
expression over degradation of that protein. 
P a g e  | 93 
P a g e  | 94 
 
P a g e  | 95 
 
P a g e  | 96 
 
P a g e  | 97 
 
P a g e  | 98 
 
P a g e  | 99 
 
P a g e  | 100 
 
P a g e  | 101 
 
P a g e  | 102 
 
 
P a g e  | 103 
5.4. Supplementary figure legends 
Supplementary Figure 1. Representative traces of multiple reaction monitoring transitions 
comparing AD hippocampus with AD motor cortex, and non-AD hippocampus with non-AD motor 
cortex: (A) peroxiredoxin 1, (B) dihydropyrimidinase-related protein 1, (C) creatine kinase B, (D) 
Go subunit , (E) -tubulin, (F) cathepsin D, (G) malate dehydrogenase, (H) dihydropyrimidinase-
related protein 2, (I) synaptotagmin 1 and (J) fructose-bisphosphate aldolase C. Key: AD, 
Alzheimer’s disease; H, hippocampus; M, motor cortex. 
 
Supplementary Figure 2. Linearity of the MRM assay. This was tested by analyzing a dilution 
series of all targeted peptides with MRM. Summed peak areas were plotted against their dilution; 
linearity was seen for all targeted peptides over the concentration range studied. 
 
Supplementary Figure 3. Traces overlaid for each peptide. Graphs representing each peptide were 
overlaid to ensure that fragment ions had the same retention time: (A) peroxiredoxin 1, (B) 
dihydropyriminidase-related protein 1, (C) creatine kinase B, (D) -tubulin, (E) cathepsin D, (F) 
malate dehydrogenase, (G) synaptotagmin 1, (H) dihydropyriminidase-related protein 2 and (I) 
fructose-bisphosphate aldolase C. 
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5.5. Supplementary figures 
Supplementary figure 1. 
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Supplementary figure 2. 
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Supplementary figure 3. 
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5.6   Additional comments 
 
The efficiency of tryptic digestion and the completeness of protein digestion can be evaluated using 
the amino acid sequence coverage, which can also define the digestion rate (Xu et al. 2010). 
Furthermore, it is important to incorporate the degree of miss-cleavage peptides into this analysis 
(Hustoft et al. 2012). Unfortunately, tryptic digestion efficiency was not controlled in the studies in 
Chapters 4 and 5. This should be addressed in future studies. 
 
For Table 4, the mean and standard deviation values have been added. 
Averaged normalized peak area 
  AD H AD M Non-AD H Non-AD M 
Peroxiredoxin 1 
Day 1 2.18  1.76  1.72  2.41  
Day 2 2.15  1.58  1.71  2.38  
Day 3 2.10  1.60  1.76  2.47  
SD 0.04  0.10  0.03  0.04  
Mean 2.14  1.65  1.73  2.42  
%CV 1.87  6.09  1.59  1.86  
Dihydropyrimidinase-related protein 1  
Day 1 1.15  0.87  1.37  1.16  
Day 2 1.12  0.79  1.29  1.16  
Day 3 1.08  0.77  1.38  1.25  
SD 0.04  0.05  0.05  0.05  
Mean 1.12  0.81  1.35  1.19  
%CV 3.27  6.06  3.77  4.47  
Creatine kinase B   
Day 1 2.22  2.46  1.63  2.24  
Day 2 2.09  2.34  1.64  2.32  
Day 3 2.10  2.52  1.53  2.23  
SD 0.07  0.09  0.06  0.05  
Mean 2.14  2.44  1.60  2.27  
%CV 3.39  3.84  3.58  2.10  
Tubulin
Day 1 28.93 31.07 38.74 38.71 
P a g e  | 121 
Day 2 25.7 28.45 37.43 38.19 
Day 3 29.07 32.18 39.42 39.78 
SD 1.91  1.92  1.01  0.81  
Mean 27.90  30.57  38.53  38.89  
%CV 6.83  6.27  2.63  2.08  
Cathepsin D 
Day 1 0.80  0.73  0.92  1.04  
Day 2 0.70  0.67  0.98  1.04  
Day 3 0.84  0.78  0.92  1.07  
SD 0.07  0.05  0.04  0.02  
Mean 0.78  0.72  0.94  1.05  
%CV 8.86  7.54  4.04  1.87  
Malate dehydrogenase 
Day 1 1.27  1.57  2.02  2.55  
Day 2 1.22  1.66  1.94  2.49  
Day 3 1.19  1.68  1.94  2.54  
SD 0.04  0.06  0.04  0.03  
Mean 1.23  1.64  1.97  2.53  
%CV 3.23  3.40  2.27  1.36  
Dihydropyrimidinase-related protein 2 
Day 1 2.88  3.26  4.06  4.63  
Day 2 2.61  2.99  3.85  4.47  
Day 3 2.84  3.22  3.97  4.50  
SD 0.14  0.14  0.11  0.08  
Mean 2.78  3.16  3.96  4.53  
%CV 5.21  4.54  2.70  1.84  
Far upstream element-binding protein 1 
Day 1 0.39  0.41  0.51  0.62  
Day 2 0.37  0.39  0.46  0.62  
Day 3 0.39  0.44  0.50  0.62  
SD 0.01  0.03  0.02  0.00  
Mean 0.38  0.41  0.49  0.62  
%CV 3.65  6.06  4.76  0.51  
Synaptotagmin 1 
Day 1 1.10  1.18  1.06  1.21  
Day 2 1.00  1.16  1.05  1.28  
Day 3 1.11  1.20  1.17  1.32  
SD 0.06  0.02  0.06  0.06  
Mean 1.07  1.18  1.10  1.27  
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%CV 5.74  2.06  5.77  4.44  
Fructose-bisphosphate aldolase C 
Day 1 1.54  1.61  1.89  2.56  
Day 2 1.45  1.56  1.84  2.51  
Day 3 1.50  1.65  1.87  2.56  
SD 0.04  0.04  0.02  0.03  
Mean 1.50  1.61  1.87  2.54  
% CV 2.91  2.77  1.20  1.21  
Key: AD, Alzheimer’s disease; H, hippocampus; M, motor cortex; SD, standard deviation; CV, 
coefficient of variation. Reproducibility was analysed by calculating the coefficient of variation of 
the summed averaged normalised peak areas across three consecutive days. 
 
The following sentence (P99, ¶10, L1-3) was rephrased for clarity.  
From: Since unmodified peptides may be derived from partially modified proteins, two or more 
peptides from each targeted protein were monitored to check for divergent regulation. 
To: For each targeted protein, peptides were individually monitored to check for divergent 
regulation.  
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5.7. Errata to published paper 
 
Figure 4 Legends A and B has been mixed up. It should be ‘Pairwise sequence alignments with 
BLAST. Pairwise alignments between human -actin and human -actin showed that: (A) peptide 
VAPEEHPVLLTEAPLNPK was sufficiently different and (B) SYELPDGQVITIGNER share 100% 
sequence homology’. 
 
 
5.8. Additional references 
Hustoft, H.K., Malerod, H., Wilson, S.R., Reubsaet, L., Lundanes, E., Greibrokk, T., 2012. A critical 
review of trypsin digestion for LC-MS based proteomics. Integrative Proteomics 73. 
Xu, F., Wang, W.H., Tan Y.J., Bruening, M.L., 2010. Facile trypsin immobilization in polymeric 
membranes for rapid, efficient protein digestion. Anal. Chem. 82, 10045-10051. 
 
  
 
 
 
 
Chapter 6 
Analysis of synaptic proteome using 
SWATH-based acquisition mass spectrometry 
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6.1. Introduction 
Current understanding of the literature is that there are around 3000 proteins in the synapses. But 
two-dimensional gel separation revealed 871 protein spots, which includes proteins with PTMs, 
isoforms and splice variants. To quantitatively study the synaptic proteome, synaptosomal fractions 
were subjected to further fractionation prior to SWATH assay. SWATH-based acquisition MS is an 
information independent acquisition (IIA) method that generates a complete recording of all 
possible ions in a biological sample in a single analysis. This technique does not require sample-
specific method development and provides high resolution quantification.  
 
6.2. Declaration of Authorship 
The contributions of all authors are stated at the beginning of the thesis. 
 
6.3. Paper in submission 
Chang, R. Y. K., Etheridge, N., Dodd, P. R., & Nouwens, A. S. (2014) Analysis of synaptic 
proteome using SWATH-based acquisition mass spectrometry. (in submission) 
 
 
 
 
 
 
 
 
 
 
Supplementary tables 1 and 2 were too big to include in this thesis. (see CD attached) 
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Abstract  
Quantitatively comparing the synaptic proteome in Alzheimer’s disease (AD) autopsy brain 
with normal aging brain is critical to understanding the molecular mechanisms associated with AD 
pathology. In this study, synaptosomal fractions isolated from hippocampus and motor cortex were 
subjected to strong cation exchange (SCX) fractionation followed by SWATH-based information-
dependent acquisition to generate a comprehensive list of ion library. A total of 2077 unique 
proteins were identified with critical local false discovery rate of <5.0%. A total of 30 proteins, 
including 17 novel proteins exhibited significant differences in abundance. Identified proteins were 
further investigated using Ingenuity’s pathway analysis to study protein-protein interactions. To the 
best of our knowledge, this is the first study to combine SCX fractionation with SWATH MS to 
establish comprehensive spectral reference library for use in SWATH analysis. Here, we show that 
SWATH is a promising new technique, which could greatly improve the number of proteins 
identified in any proteome, as well as many other benefits; however, there are limitations yet to be 
resolved that will require advances in MS/MSALL with SWATH™ Acquisition MicroApp (version 
1.0) software. Peptide MS/MS sequences could not be confidently matched to the theoretical 
sequence, and/or observed retention time of precursor ions differed greatly from predicted retention 
times. 
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Introduction 
The pathological hallmarks of Alzheimer’s disease (AD) are intracellular neurofibrillary 
tangles, extracellular amyloid plaques and neuronal loss. The pathology is region-specific: the 
hippocampus is severely affected whereas occipital and motor cortices are relatively spared
1
. 
Increasing evidence suggests that synaptic dysfunction and degeneration may underlie disease 
progression. Severe synaptic and neuronal degeneration is observed in parts of the AD brain
1, 2
, and 
the degree of degeneration strongly correlates with the deterioration of cognitive abilities ante 
mortem
2
. However, the molecular mechanism that leads to synaptic loss is unclear. 
Proteomics combined with subcellular fractionation allows the analysis of less abundant 
proteins by reducing sample complexity. Previous studies assessed the abundance of proteins from 
synaptosomal
3
, nuclear
4
, cytosolic
5
 and mitochondrial fractions
6
 in human autopsy brain. We used 
two-dimensional gel electrophoresis on human brain synaptosome extracts and identified 1000 and 
~1700 proteins in separate studies
3, 7
; these numbers include isoforms and proteins with post-
translational modification (PTM). Liquid chromatography (LC) separation with tandem mass 
spectrometry (MS/MS) allowed over 1400 proteins to be quantified in whole brain tissue
8
. These 
numbers are low considering that over 3000 proteins are currently estimated to occur in human 
synaptic endings, excluding isoforms and post-translationally modified forms
9
. 
For protein quantification by MS/MS, multiple reaction monitoring, in which proteotypic 
peptides of a protein of interest are targeted, is highly sensitive and reproducible. Ions within a 
narrow range of mass to charge (m/z) ratio values around that of the target precursor ion are 
transmitted in the first spectrometer quadrupole. The precursor ion is fragmented in the second 
quadrupole by collision-induced dissociation, and the third quadrupole then transmits ions in a 
narrow m/z range around those of the target fragment ion. A major drawback of this approach is the 
significant investment in development required for each peptide of interest, which currently limits 
assays to ~100 transitions per run
10
. 
The non-targeted quantification technique SWATH (sequential window acquisition of all 
theoretical fragment-ion spectra) utilizes information-independent acquisition to scan a useful mass 
range using wide precursor-isolation windows to collect fragment-ion spectra, at high resolution, for 
all analytes detected in a sample
10
. In standard SWATH acquisition, 32 windows of 25 Da are 
sequentially selected in the first quadrupole. In the second quadrupole, transmitted ions are 
fragmented and the product ions then detected in the ToF mass analyser (Fig. 1). SWATH 
acquisition generates a 3D fragment-ion m/z intensity-retention time map for each precursor 
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isolation window. A parallel information-dependent acquisition (IDA) experiment is used for 
protein identification and to generate a reference map of all the precursor and fragment ions in the 
sample, which permits targeted data extraction to correlate fragment-ion peaks for peptide 
quantification. SWATH provides accurate quantification and high throughput
10, 11
 comprehensive 
data, and post-acquisition data mining without upfront assay development. A major advantage is the 
greater number of MRM-quality assays that can be performed simultaneously. SWATH has been 
used to quantify proteins in human plasma
11
 and cells
12
, and to study protein interaction dynamics
13
. 
However, it has not yet been applied to synaptosomes from human AD autopsy tissue. 
Here, we fractionated synaptosome extracts by strong cation exchange (SCX) prior to 
SWATH IDA to generate a comprehensive list of all fragment ions detectable. AD pathology is 
region specific: some parts of the brain are more heavily affected than others. Tissue samples were 
obtained from human subjects that were highly variable in age, cause of death, medication, and 
many other factors. To counter these potential confounds, a vulnerable region (hippocampus) was 
compared with a relatively spared region (motor cortex) within each group. Then, the difference in 
abundance detected in the within-AD comparison was compared with that in the non-AD 
comparison. To the best of our knowledge, this is the first study to quantify synaptosomal fractions 
from human autopsy tissue by SWATH. A total of 30 proteins showed greater than 1.5-fold change 
(FC) between AD and non-AD comparisons. 
Materials and methods 
 Tissue collection and storage 
Brain tissue was obtained from the Queensland Brain Bank, School of Chemistry and 
Molecular Biosciences, University of Queensland with written consent from the next of kin. 
Queensland Brain Bank is a Brisbane node of the Australian Brain Bank Network supported by the 
National Health and Medical Research Council. Post-mortem histopathological examination was 
conducted by qualified pathologists to confirm AD diagnosis using Australian guidelines under the 
CERAD criteria
14
. Control subjects did not meet these criteria. Tissue samples were immersed in 
ice-cold isotonic (0.32 M) sucrose at autopsy for cryoprotection. The tissue was slowly frozen and 
stored at –80°C until use. This study was approved by the Medical Research Ethics Committee of 
University of Queensland ( 0000105). 
 Case Selection 
Clinical information including age, post-mortem interval, brain weight, and cause of death 
was acquired from the Queensland Brain Bank database. Pathologically affected region 
(hippocampus) and relatively spared region (motor cortex) was obtained from six female AD cases 
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(71–87y) and six female controls (71–91y). This controlled for case-to-case variation in post-
mortem interval and age-related factors
15
; age and post-mortem interval was matched as closely 
possible. All subjects were of Northern European ancestry; however, ethnicity has no significant 
effect on AD progression
16
. Clinical details of the cases are described in Table 1. 
Subcellular fractionation 
Synaptosomes were prepared as per
7
 with minor modifications. In brief, 0.5 g of tissue was 
used from each cortical region. Brain samples were homogenized with a motor-driven Teflon-glass 
homogenizer with 5 mL of ice-cold 0.32 M sucrose with phosphatase inhibitor cocktail (1 mM 
sodium orthovanadate, 10 mM sodium pyrophosphate, 2 mM glycerol phosphate and 30 mM 
sodium fluoride). Homogenized mixture was centrifuged at 750 x g (J20 rotor J26-XPI centrifuge, 
Beckman Coulter P/L, Lane Cove, NSW, Australia) for 10 min at 4°C. The supernatant was further 
centrifuged at 19 000 x g for 20 min at 4°C. The pellet was resuspended in 5 mL 0.32 M sucrose, 
and then layered over a sucrose gradient consisting of 0.5 M sucrose above 1.2 M sucrose. Sucrose 
gradient was centrifuged at 82 500 x g in a swinging bucket rotor (SW41Ti, Beckman L8-60M 
ultracentrifuge) for 2 h at 4°C. Synaptosomal fraction was obtained by collecting the layer between 
0.8 M and 1.2 M sucrose by aspiration. 
 Sample preparation 
A 1/9 volume of 0.4% deoxycholic acid was added to synaptosomal fraction and incubated 
on ice for 30 min. The mixture was incubated with 1/9 volume of 1 M trichloroacetic acid for 
further 60 min. After centrifuging the sample at 10 000 x g for 10 min at 4°C, 1 mL of ice-cold 90% 
(v/v) acetone was added to the pellet followed by brief vortexing. The mixture was incubated at –
20°C overnight. Next day, the samples were centrifuged at 10 000 g for 20 min at 4°C. The pellets 
were dried for 5 min, and then resuspended in 25 µL of 8 M urea, 2 M thiourea in 50 mM 
ammonium bicarbonate. A 2D-Quant kit was used to determine protein concentration (GE 
Healthcare Life Sciences, Rydalmere, NSW, Australia). An aliquot (5 µg) of each samples and a 
pooled sample (30 µg) were brought to 5 mM dithiothreitol and incubated for 120 min at room 
temperature. Iodoacetamide was added to bring the final concentration to 25 mM and incubated for 
30 min in the dark. Dithiothreitol was added to a final concentration of 10 mM to quench excess 
iodoacetamide. Samples were diluted to 2 M urea with 50 mM ammonium bicarbonate. Trypsin was 
added to the samples at 1:100 (enzyme:protein) ratio, and incubated for 6 h at 37°C. Then, an equal 
amount of trypsin was added, followed by overnight incubation at 37°C. Trypsin-digested peptides 
were purified and concentrated using a ZipTipC18 (10 µL tip with 0.6 µL resin bed, Millipore, 
Billerica, MA, USA) according to the manufacturer’s instructions. A pooled sample was subjected 
to SCX fractionation prior to LC-MS/MS. 
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 Strong cation exchange fractionation 
The samples were dissolved in buffer A (0.5% acetic acid, 2% acetonitrile), and fractionated 
by SCX chromatography using Agilent 1100 series LC system (Agilent Technologies, Mulgrave, 
Vic, Australia) equipped with a ZORBAX BioSCX-Series II column (Agilent Technologies, 50 mm 
× 2.1 mm, 3.5 µm). The peptides were eluted over 32 min at 0.1 mL/min with following linear 
gradients: 0% buffer B (0.5% acetic acid, 2% acetonitrile, 250 mM ammonium acetate) for 3 min, 
0–15% buffer B for 2 min, 15–50% buffer B for 17 min, 50–80% buffer B for 3 min, 80% buffer B 
for 5 min, and 80–0% buffer B for 2 min. One-minute samples (100 µL) were collected for 37 min; 
eluate samples ##1–12 were combined to give Fraction 1, ##13–14 Fraction 2, #15 Fraction 3, #16 
Fraction 4, #17 Fraction 5, #18 Fraction 6, ##19–20 Fraction 7, and 21–37 Fraction 8. Fractions 
were vacuum concentrated followed by ZipTip18 desalting. Each was analysed separately on a 
Triple-ToF 5600 MS for IDA analysis. 
 HPLC-TripleToF 5600 mass spectrometer 
Samples were analysed using a Shimadzu Prominence nanoLC connected to a Triple-ToF 
5600 (AB SCIEX, Framingham, MA, USA). Mobile phases AT and BT were 1% acetonitrile/ 0.1% 
formic acid and 80% acetonitrile/ 0.1% formic acid, respectively. SCX-separated fractions 1–8 (~1 
µg) and unfractionated samples (1 µg) were loaded onto the autosampler maintained at 12°C, then 
trapped in a 150 µm × 150mm, 5 µm C18 column and desalted for 3 min with 100% mobile phase 
AT at a flow rate of 30 µL/min. Injection volume was 10 µL (1 µg) for standard IDA experiments 
and 15 µL (1 µg) for SWATH experiments. Chromatographic separations were performed using a 
Vydac Everest C18 column (150 µm ID × 150 mm, 300A, 5 µm particle size; Mandel Scientific, 
Guelph, ON, Canada) with following linear gradient: 10% buffer BT from 0–3.01 min, 10–60% 
buffer BT from 3.01–48 min, 60–97% buffer BT from 48–56 min, 97% buffer BT from 56–61 min, 
97–10% buffer BT from 61–63 min, and 10% buffer BT from 63–70 min, at a flow rate of 1 µL/min. 
Eluted peptides were detected by TripleToF 5600 MS (AB SCIEX) coupled with a Nanospray III 
ion source in positive ion mode using PicoTip Emitter SilicaTips (12 cm, 10 µm diameter, uncoated; 
New Objective, Woburn, MA, USA). The following MS conditions were used: declustering 
potential of 80 V, curtain gas of 30 psi, Gas #1 of 10 psi and interface heater temperature of 150°C. 
IDA experiment 
For TOF MS scans, ions with m/z values between 350 and 1800 were analysed with an 
accumulation time of 0.5 s. For MS/MS, ions between m/z 40 and 1800 were acquired in high-
sensitivity mode with accumulation time of 0.05 s, and up to 20 product ions with 2+ to 5+ charge-
state were collected if they exceeded an intensity threshold of 100 cps. Total cycle time was 1.55 s. 
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For each scan, four time bins were summed with 1.059 ms pauses between mass ranges. For 
collision-induced dissociation, a sweeping collision energy of 40 ± 15 V was applied. The MS was 
auto-calibrated using a tryptic digest of 5 fmol of -galactosidase by using peptides at m/z 534.2489, 
542.2645, 550.2802, 671.3379, 714.8469 and 729.3652, and fragment ions of the peptide at m/z 
729.3652 for MS/MS mode. Each SCX fraction 1–8 was run separately and was repeated three 
times. 
SWATH experiment 
For SWATH–based experiments, the MS was operated in a looped product ion mode. For 
MS1 scan, the mass range of 350–1800 Da was analysed with an accumulation time of 50 ms. A set 
of 34 overlapping windows was then constructed with an isolation width of 26 Da (contains 1 Da 
for the window overlap
10
) to cover the mass range of 400–1250 Da (cycle time pf 3.33 s). The 
collision energy was independently determined using Analyst software (AB SCIEX) for each 
window based on the calculation for a 2+ ion centered upon the window with a collision energy 
spread of 15 V, linearly across the accumulation time (95.1 ms). Fragment-ion scans were in high-
sensitivity mode. Individual samples used for SWATH analysis were not subjected to SCX 
fractionation. 
IDA data analysis 
ProteinPilot software v. 4.5 (AB SCIEX) was used to process IDA data. ProteinPilot uses the 
Paragon algorithm
17
 to search against the Uniprot database. IDA files from triplicate runs of 
Fractions 1–8 were combined for the search. False discovery rate analysis was done with tools 
integrated in the software. False discovery rate analysis uses decoy database to search for decoy 
proteins (known to be wrong) as well as the target proteins. By comparing the number of decoy 
proteins with the number of target proteins, the error rate is estimated. Thorough ID search setting 
was selected with the following criteria: identification; cysteine alkylation, iodoacetamide; 
digestion, trypsin; fixed modification, carbamidomethylation; variable modification, oxidation of 
methionine; and detected protein p-value threshold was set to 0.05. 
Data processing and statistical analysis 
ProteinPilot results were exported to PeakView software (AB SCIEX) for identification, 
quantification and alignment of spectral peaks. Shared peptides and peptides with confidence level 
below 99 % were excluded. Number of peptides was set to 10 and transitions to 6. An ion library 
was created in PeakView for statistical analysis using MSstats. MSstats is a R-based statistical 
software which (1) transforms and normalizes the peak intensities, (2) automatically detects the 
experimental design from the data, and (3) fits an appropriate linear mixed model. The peak areas, 
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representing protein abundance, were transformed to log2-base and then normalised to equal out 
median endogenous intensities across runs. Two comparisons were made: AD hippocampus vs. AD 
motor cortex and non-AD hippocampus vs. AD motor cortex. Proteins that showed greater than ± 
1.2-fold difference with adjusted p-value of < 0.05 were subjected to further analysis. Each spectral 
peak was manually inspected in PeakView software to confirm the identity of the selected peak. The 
retention time of selected peptides from SWATH acquisition were crosschecked with the reference 
map. MS/MS spectra were carefully checked to confirm the peptide sequence by matching it to the 
theoretical fragment ions; peptides that could not be confirmed were removed from the ion library. 
Peptides with spectral peaks with intensity lower than 800 were excluded. Proteins with less than 
two peptides were excluded. Peptides containing potential post-translational modification sites, 
according to Uniprot, were noted. The updated ion library was subjected to further statistical 
analysis in MSstats. Proteins that showed greater than ± 1.2-fold difference with adjusted p-value of 
< 0.05 were considered significant. 
 Pathway analysis 
Differentially expressed proteins were subjected to Ingenuity Pathway Analysis (IPA) 
software (Ingenuity Systems, Redwood City, CA) to evaluate the most relevant interaction networks 
and to identify proteins Protein accession numbers were imported into IPA for analysis. IPA 
generates protein interaction networks in silico based on protein-protein interactions and 
associations mined from the peer-reviewed literature. Proteins were represented as nodes and 
biological associations between nodes were linked. Functional types of the protein were represented 
using different node shapes (See Fig. 3). 
Results 
 Reference map 
To generate spectral libraries for a reference map of the synaptosomal fraction from human 
brain, a pooled sample from AD and non-AD hippocampus and motor cortex was analysed. The 
pooled sample was divided into 8 fractions by SCX; each fraction was analysed separately, in 
triplicate, using SWATH-based IDA LC-MS/MS. Results were analysed together using ProteinPilot 
Software, which uses the Paragon algorithm for protein identification. The independent false 
discovery rate of the Paragon algorithm results was determined by the Proteomics System 
Performance Evaluation Pipeline. A total of 2077 different proteins were identified (Supplementary 
table 1) that had a critical local false discovery rate of <5.0%. This is ~1800 more identifications 
than SWATH-based IDA analysis without prior SCX-fractionation (Supplementary table 2). For 
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each peptide, precursor ion sequence, mass, charge and chromatographic retention time, and 
fragment ion mass, charge and relative intensities were collected. 
 Differentially expressed synaptic proteins 
Proteins showed both up-regulation and down-regulation in AD hippocampus and non-AD 
hippocampus when compared with AD motor cortex and non-AD motor cortex, respectively (Table 
2). In AD hippocampus, two proteins showed greater than 4-fold difference, 104 proteins showed 2-
to4-fold difference, 385 proteins showed 1.4- to 2-fold difference, and 1586 proteins showed 
greater than 1.2-fold difference. In non-AD hippocampus, two proteins showed greater than 4-fold 
difference, 67 proteins showed 2- to 4-fold difference, 302 proteins showed 1.4- to 2-fold difference, 
and 1706 proteins showed greater than 1.2-fold difference. Proteins with p-value less than 0.05 and 
> 1.2-fold difference were considered significant. In total, 68 proteins showed significant 
differences in abundance between AD or non-AD hippocampus when compared with motor cortex, 
and showed greater than 1.5-fold differences between AD log2FC and non-AD log2FC. Transitions 
representing each peptide that belongs to these proteins were manually inspected to exclude (i) 
noise-like signals, (ii) peptides with MSMS spectra that could not confidently be matched to 
theoretical MSMS spectra, (iii) peptides with known PTM sites, and (iv) peptides that had different 
retention time to the spectral library built from IDA analysis. The same statistical test was 
conducted again with these peptides excluded, and found that 30 unique proteins showed greater 
than 1.5-fold differences between AD and non-AD comparisons (Table 2). Transitions used for 30 
proteins are presented in Supplementary table 3. 
 Pathway analysis 
Proteins exhibiting differences in abundance were further analysed by IPA core analysis to 
gain insight into the most relevant cellular functions and networks altered in AD, and to identify 
other closely associated proteins. The most perturbed molecular and cellular functions in AD 
hippocampus were cellular assembly and organization, cellular function and maintenance, cell-to-
cell signalling and interaction, cell morphology, and cellular development. The top diseases and 
disorders was neurological diseases, and the top physiological system development and function 
was nervous system development and function. Core analysis revealed RhoA signalling (septins 2, 5, 
7, 8, 9 and 11 are associated) to be the top canonical pathway, followed by signalling by Rho family 
GTPases (RhoG and septins 2, 5, 7, 8, 9 and 11 are associated) (Fig. 2). Network analysis showed 
that differentially expressed proteins were related to cellular assembly and organization, cellular 
function and maintenance, and nervous system development and function. This top-ranked network 
was visualized in IPA, which revealed other closely associated proteins (Fig. 3): ubiquitin C, 
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serine/arginine repetitive matrix 2, sirtuin 7, tubulin 3 chain, tubulin 4B chain, septin 9, and 
presenilin 1. 
Discussion 
In this study, we have used SWATH-based mass spectrometry to compare the levels of 
synaptosomal proteins from AD and non-AD hippocampus and motor cortex. Gillet et al showed 
that SWATH-based protein quantification is highly consistent and accurate, and provides MRM-like 
quality
10
. This is the first study to use SCX-fractionation prior to SWATH-based IDA to generate a 
comprehensive reference map of a proteome. We reduced sample complexity by dividing the 
samples into 8 different fractions, each of which was analysed separately. Spectral data from each 
fraction were combined to generate a reference map of 2077 unique proteins. Without prior SCX-
fractionation, around 536 proteins were identified using SWATH-based IDA analysis. This showed 
that reducing sample complexity greatly increases the likelihood of identifying less abundant 
proteins, which may have been undetected due to the matrix effect. 
SWATH data processing software version is in early stages of development. We found that 
the software often selected a peak that does not belong to the target peptide: (i) its retention time 
differed greatly when cross-checked with the reference map; and/or (ii) the peptide sequence could 
not be confirmed when MS/MS spectra were matched to the theoretical fragment ions. For example, 
PeakView software suggests that peptide NLLHQDAVDLFT (3+) from synaptojanin-2-binding 
protein was eluted at 16.9 min (Fig. 4a); however, the MS/MS spectrum at 16.9 min does not relate 
to the target peptide sequence. Rather, the peptide sequence could be confirmed at 17.6 min (Fig. 4c 
and d). Unfortunately, the user cannot deselect the spectral peak that the software chooses and 
reselect the correct one. In addition, it is unreliable to depend solely on the accuracy of retention 
time (Fig. 5). The observed retention time of peptide ESIDLVLDR from tubulin -8 chain was 20.9 
min, whereas the reference map states 15.9 min. When the MS/MS spectrum of the peptide was 
checked, the spectral peak was seen to truly represent the target (Fig. 5b and c); only peptides 
manually confirmed as correct were quantified. 
In total, 30 unique proteins showed (i) significant differences in their abundance between 
AD hippocampus and AD motor cortex and/or non-AD hippocampus and non-AD motor cortex, 
and (ii) greater than 1.5-fold differences in AD log2FC and non-AD log2FC. Abundance differences 
were considered significant if log2FC ≥ 0.3 and p-value < 0.05. 
Of these, 13 proteins have previously been implicated in AD pathology, and 17 are novel 
proteins (Table 3). This study alone does not show the mechanisms underlying synaptic dysfunction 
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in AD pathogenesis, but altered abundance could potentially be detrimental to synaptic function. 
The altered proteins were classified into functional groups. 
 Structural proteins 
The abundance of structural proteins including the septins, adhesion molecules, neurofilaments, 
tubulin, and tubulin polymerization-promoting protein differed in AD hippocampus. Altered levels 
of abundance of structural proteins might impair structural integrity and axonal transport 
mechanism and lead to synaptic atrophy. 
We identified septin-2, 3, 4, 5, 6, 7, 8, 9 and 11 in the synaptosomal fraction, and were able to 
quantify all. For septin-3, proteotypic peptides detected in IDA analysis belonged to both isoforms 1 
and 2, but not 3. Hence, the difference did not represent global septin-3 abundance, nor was it 
isoform-specific. As a result, septin-3 was excluded from further analysis. Six proteotypic peptides 
(with >99 confidence score) were used to identify septin-5. Of these, four 
(ELKESAPFAVIGSNTVVEAK, ESAPFAVIGSNTVVEAK, STLVHSLFLTDLYK and 
STLVHSLFLTDLYKDR) are in all isoforms, and two (MESPIPILPLPTPDAETEKLIR and 
MESPIPILPLPTPDAETEK) are specific to isoform 1. The latter two sequences differ by only three 
amino acids. Although the use of transitions from two peptides was considered acceptable, we felt it 
would be unreliable to depend on two peptides that shared the same peptide sequence 
‘MESPIPILPLPTPDAETEK’. One proteotypic peptide was detected for septin-8 isoform 1. 
Because using transitions from a single peptide is not reliable for quantification, septin-8 isoform 1 
(SLSLGGHVGFDSLPDQLVSK) could not be confidently analysed. 
Septin-4 and septin-6 did not show significant differences in abundance, while all other septins 
examined showed significantly lower levels in AD hippocampus than in AD motor cortex. Septin-8 
and -11 differences in abundance were reported in our previous AD study using two-dimensional 
gel electrophoresis
3
. Septin-8 was identified from two protein spots where one showed significantly 
higher abundance and one showed no change in AD hippocampus. In temporal cortex, septin-11 
abundance was higher in non-AD brain and no difference was seen in AD brain. The two-
dimensional gel results could reflect a difference in abundance of the isoform and/or PTMs, which 
will be invaluable information when the nature of the modification is determined. SWATH results 
reported here are global differences, not isoform switching or modifications. Previous studies have 
shown that lower septin-2, 5, 7
18
 and 11
19
 expression disturbs the cytoarchitecture of spines and 
dendritic arborisation. Septin-5 may be involved in exocytosis by regulating SNARE function
20
 and 
septin-11 plays a role in aminobutyric acid-ergic synaptic connectivity19. Since septins are 
functionally related to vesicle trafficking and the cytoskeleton, they may be essential for 
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neurotransmitter release and the regulation of axon development. Thus, down-regulation of septins 
could alter neurotransmission and synaptic structure in AD hippocampus. 
This is the first study to show significant abundance differences in AD hippocampus synapse. 
Contactin-2 is a cell adhesion molecule, highly expressed at the axon, which regulates axon 
guidance and neurite outgrowth
21
. A knockout mice study demonstrated that contactin-2 is essential 
for regulating normal learning and memory
22
. We found significantly lower abundance of contactin-
2 in AD hippocampus and non-AD hippocampus than in AD motor cortex and non-AD motor 
cortex respectively; the difference was more than 3-fold in AD hippocampus. Gautam et al.
23
 
reported that contactin-2 abundance was lower in AD temporal cortex than in age-matched control 
samples. Thus, contactin-2 may be down-regulated in whole tissue as well as within synapses in 
AD-affected areas. This may alter their functions and cause structural damage by perturbed cellular 
adhesion. 
Previous studies have shown lower abundance of internexin (INA) in an AD transgenic mouse 
model
24
, and higher abundance in postsynaptic densities from AD cortex obtained at autopsy
25
. In 
this study, we found significantly lower abundance of  in the synaptosomal fraction from AD 
and non-AD hippocampi compared with AD and non-AD motor cortices respectively (Suppl. Fig. 
1); however, the extent of difference was more than two-fold in AD hippocampus. A similar 
decrease was seen in neurofilament light polypeptide (NFL) and neurofilament medium polypeptide 
(NFM) transcript in AD brain using Northern blot by Kritter and colleagues
26
. This suggests that the 
loss of INA in the pre-synapse is severe in AD brain. Significantly lower levels of these structural 
proteins in the synapses of AD hippocampus may alter synaptic morphology and lead to 
dysfunction. 
Three proteins associated with microtubules were differentially abundant in AD hippocampus: 
tubulin -4A chain, tubulin -4A chain, and tubulin polymerization-promoting protein. Our 
previous study showed lower abundance of tubulin polymerization-promoting protein in AD 
temporal cortex
3
. Here, we show it is also significantly less abundant in AD hippocampus. The 
levels of tubulin -4A chain and tubulin -4A chain were also lower in AD hippocampus. This is 
the first report of reduced abundance of these two tubulin proteins in AD hippocampal synapses. 
Altered levels of these microtubule-associated proteins may affect axonal transport and promote 
synaptic degeneration in AD hippocampus. 
Signalling 
We found poly C-binding protein 1 in the synaptosomal fraction from human brain. It is difficult to 
predict the exact role of this multifunctional protein in the synapse; however, a lower level in the 
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synaptosomal fraction of AD hippocampus suggests possible disruption of gene regulation, 
including the regulation of the -opioid receptor27. The opioid system is involved in cognitive and 
memory functions, and is affected in AD brain where there significantly reduced numbers of -
opioid receptors
28
. Hence, low levels of poly C-binding protein 1 may disrupt the opioid system and 
cause cognitive decline in AD brain. 
Another protein involved in signal transduction is EH domain-containing protein 3. In a knockout 
study of this protein, secretion of amyloid  was significantly reduced in hippocampal neurons29. 
Our previous work using 2D gels showed significantly lower levels of a protein spot representing 
the EH domain-containing protein 3
3
. Down-regulation of this protein may be a protective 
mechanism deployed by AD hippocampus to reduce the level of amyloid , and consequent 
pathogenesis. 
Versican is an extracellular matrix protein that is present in four different isoforms, V0, V1, V2 and 
V3, each with a different function. Peptides used for versican quantification were not specific for 
any isoform, but rather represented global protein abundance. We suspect that the low level of 
versican protein may reflect that of isoform V2 because it is the dominant isoform in mature brain
30
. 
Isoform V2 is involved in glutamatergic synaptic transmission and inhibition of neurite outgrowth 
by organising the extracellular matrix assembly
31
. Hence, low levels of versican protein may alter 
the regulation of synaptic transmission and structure, both of which are observed in AD 
hippocampus. 
The abundance of RhoG protein was significantly lower in AD hippocampus while no significant 
difference was observed in non-AD hippocampus.  A low level of RhoG may disturb Rho 
signalling in AD hippocampal synapses and alter the pathways the protein is involved in to cause 
structural and functional dysfunction. 
Src kinase signalling inhibitor 1 (SRCIN1) inhibits Src activity and downstream signalling. 
SRCIN1 abundance was significantly lower in AD hippocampal synapses, which could lead to over-
activation of NMDAR function. This may cause excitotoxicity from receptor overstimulation by the 
excitatory neurotransmitter, a common pathology observed in AD brain. In addition, SRCIN1 may 
be involved in regulating exocytosis by acting as a linker protein connecting synaptosome-
associated protein of 25 kDa to the actin cytoskeleton
32
. A recent study showed that SRCIN1 
interacts with synaptophysin, a presynaptic vesicle membrane protein
33
. These studies together 
suggest a possible role for SRCIN1 in synaptic dysfunction as a consequence of excitotoxicity and 
disturbed neurotransmitter release. 
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Another protein involved in vesicular exocytosis and neurotransmitter release, rabphilin 
3A
34
, was also less abundant in AD hippocampus. A recent study reported significantly lower levels 
of this protein in AD neocortex obtained at autopsy
35
, further supporting the hypothesis that 
neurotransmitter release is disturbed in AD. 
Autophagy 
The aminobutyric acid type A receptor-associated protein-like 2 is involved in the 
autophagy of damaged mitochondria. Currently, it is not clear as to whether overactive, pathologic 
autophagy or insufficient protective autophagy is associated with ageing. We found a significantly 
lower level of this protein in non-AD hippocampus, and no significant difference in AD 
hippocampus. Our finding supports the former hypothesis, that excessive pathologic autophagy 
could damage synapses in AD. 
Oxidative stress 
The levels of NADP transhydrogenase and peroxiredoxin-2 isoform 1 were significantly 
lower in AD hippocampus synapses but no difference was seen in non-AD hippocampus. In contrast, 
peroxiredoxin-2 abundance is reportedly higher in whole tissue homogenates of AD hippocampus
36
. 
This discrepancy suggests altered protein or mRNA trafficking to the synapse, which would result 
in decreased antioxidant capacity in an area where it is most needed in AD. High levels of reactive 
oxygen species, as occurs in AD synapses, damage peroxiredoxin-2
37
. 
Proteasome 
A previous study found higher levels of proteasome complexes, rpt1 subunits, and 
hyperphosphorylated tau in the synaptosomal fraction from AD brain
38
. Highly insoluble and 
hyperphosphorylated tau protein aggregation induces ubiquitin immunoreactivity in AD brains
39
, 
which could explain the increase in proteasome levels in AD synapses. We found significantly 
higher abundance of proteasome subunit  type-6 in AD hippocampal synapses, whereas no 
significant difference was observed in non-AD hippocampus. In AD brain, the ubiquitin-proteasome 
system may become disrupted through overloading or malfunctioning of ubiquitinated proteins
40
. 
Since the proteasome degradation system is essential to regulating the integrity of the synapse, its 
disturbed function could lead to synaptic dysfunction. 
Synaptic versicle-related proteins 
We found three synaptic vesicle-related proteins that were differentially abundant in AD 
brain. Synapsin-2 levels were higher in human AD hippocampus (Suppl. Fig. 2), which corroborates 
with another study that found up-regulation of synapsin-2 in a transgenic mouse model of AD
41
. 
Higher abundance may be part of a compensatory mechanism for the loss of synaptic endings and 
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consequent impaired neurotransmission. Vesicle amine transport 1 abundance was significantly 
higher in non-AD hippocampus but no difference was seen in AD hippocampus. Higher levels in 
non-AD hippocampus may reflect a protective mechanism against age-related loss of synapses in 
normal aging, a mechanism that is lost in AD. Another differentially expressed vesicle-related 
protein is zinc transporter 3. Zinc transporter 3 mRNA level is lower by up to 60% in AD-affected 
areas in human autopsy brain
42
. Zheng et al. showed higher zinc transporter 3 protein level in cortex 
in an AD transgenic mouse model
43
, and our study using human AD brain supports this. Higher zinc 
transporter 3 levels in AD hippocampus would increase Zn
2+
 released in the synapses, accelerating 
plaque formation by directly binding to amyloid 44 
 Energy-related 
We found significantly less oxoglutarate dehydrogenase complex component E2 in AD and 
non-AD hippocampus, but the extent of difference was greater in AD brain. Oxoglutarate 
dehydrogenase complex activity is diminished in AD
45
. Hence, the extent of enzyme activity 
reduction could be greater than the loss of protein indicates. Reduced abundance and activity in 
synapses could impair glutamate metabolism, causing neuronal cell death in AD. 
Unknown function 
Two proteins with unknown function, WD repeat-containing protein 37 and peptidyl-prolyl 
cis-trans isomerase-like 1 were differentially expressed. Significantly lower abundance of WD 
repeat-containing protein 37 was found in AD hippocampus while no significant difference was 
seen in non-AD hippocampus. The function of this protein is unknown; it could be involved in 
cellular processes that include signal transduction, gene regulation, and apoptosis
46
. Peptidyl-prolyl 
cis-trans isomerase-like 1 abundance was significantly higher in synaptosomes from AD 
hippocampus. Overexpression has been implicated in growth of colon cancer cells by remodelling 
microtubules
47
. Under physiological condition peptidyl-prolyl cis-trans isomerase-like 1 may play a 
role in protein folding and pre-mRNA splicing
48
; however, its function at the synapse is unknown. 
 Pathway analysis 
Thirty differentially regulated synaptic proteins were further analysed using IPA core 
analysis and pathway analysis. Core analysis revealed that the most-affected molecular and cellular 
functions were cellular assembly and organisation, cellular function and maintenance, cell-to-cell 
signalling and interaction, cell morphology, and cellular development. Structural proteins including 
INA, NFL, NFM, NFH and the septins were involved in various cellular assembly and 
organisations such as organisation of cytoskeleton, dendritic growth/branching, and organisation, 
clustering and dissociation of neurofilaments. Structural proteins (NFH and MNFM
49
), an adhesion 
P a g e  | 140 
molecule (contactin-2
50
), signalling proteins (RhoG
51
 and versican
52
) plays roles in the growth of 
neurites. Proteins rabphilin, septin 5 and synapsin-2 are involved in the release of neurotransmitter
35, 
53, 54
. All these functions could be affected in AD hippocampus due to differences in abundance.. 
The top-ranked network shown by IPA core analysis was visualised. Proteins including 
ubiquitin C, serine/arginine repetitive matrix 2, sirtuin 7, tubulin -3 chain tubulin -4B chain, 
septin 9 and presenilin 1 were closely associated with synaptic proteins that are differentially 
regulated in AD-affected areas. Ubiquitin C, a member of ubiquitin family, binds to septins 2, 5, 7, 8, 
9 and 11, peptidyl-prolyl cis-trans isomerase-like 1, oxoglutarate dehydrogenase complex 
component E2, tubulin   -aminobutyric acid receptor-associated 
protein-like 2, NADP transhydrogenase, mitochondrial, contactin-2, INA, synapsin-2, NFL, NFM 
and NFH. Ubiquination is associated with various cellular functions including endocytosis, protein 
degradation, kinase modification, and regulation of other cell signalling pathways. It would be 
interesting to study how altered levels of these proteins could affect their binding to ubiquitin C, 
and the resulting functional outcome in AD. Pathway analysis also showed that sirtuin 7 binds to 
tubulin, NFM, NFL and INA. However, the functions of human sirtuins have not yet been 
determined. Presenilin 1 is well known for its involvement in AD. Martin’s group suggested its 
potential role in regulating the expression of tubulin polymerization-promoting protein and tubulin 
-4A chain55. It will be interesting to further explore these newly identified proteins with SWATH 
data mining and/or functional studies. 
Conclusion 
In summary, we used two front-end sample processing techniques – subcellular fractionation 
and SCX fractionation – with SWATH acquisition-based MS analysis to identify over 2000 proteins 
within the synapses of human AD brain. Furthermore, we quantitatively analysed those proteins and 
found that 30 unique synaptic proteins are differentially expressed in AD hippocampus, which 
includes 17 novel proteins. SWATH is a relatively new technique, which have rooms for 
improvement as we discussed in section 4. With improved and user-friendly data processing 
software, SWATH analysis would definitely be a useful tool for studying scarce samples like human 
brain. Proteins identified in this study could potentially be used for disease marker and drug-target 
development. 
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Table 1. Case information 
Age (y) PMI (h) Brain Weight (g) Cause of death 
Non-AD subjects 
69.67 23.0 1166 Hypostatic Pneumonia 
71.10 7.8 1204 Sudden cardiac death 
75.78 48.8 1210 Pneumonia 
77.57 18.0 1272 Respiratory arrest 
83.65 26.0 1157 Pulmonary Embolus 
87.38 27.0 1398 Not determined* 
AD cases 
71.33 27.0 1140 Not determined* 
78.51 7.5 990 Alzheimer’s disease 
82.06 41.3 1100 Not determined* 
84.79 35.6 1187 Dementia 
89.51 19.5 1040 Not determined* 
90.67 46.8 1100 Pneumonia, dementia 
Note: The Cause of Death certificate was used by the Queensland Brain Bank to determine the 
cause of death. In some cases (*) the cause of death was not recorded. 
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Table 2. Number of proteins that showed up-regulation or down-regulation in each AD and non-AD 
comparisons.  
 AD Non-AD 
Hippocampus vs. Motor cortex Hippocampus vs. Motor cortex 
Up-regulated 711 1170 
Down-regulated 1366 907 
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Table 3. Proteins identified with significant expression differences in hippocampus compared with motor cortex in AD and non-AD patients.  
Accession # Gene name Name 
AD 
(Hippocampus vs Motor) 
Non-AD 
(Hippocampus vs Motor) 
Fold 
difference 
p-value 
Fold 
difference 
p-value 
Q16352 INA -internexin * -2.3 < 0.001 -1.4 < 0.001 
Q02246 CNTN2 Contactin 2 * -2.1 < 0.001 -1.2 0.360 
P13611 VCAN Versican core protein -2.0 < 0.001 -1.4 < 0.001 
Q9NZN3 EHD3 EH domain-containing protein 3 * -1.2 < 0.001 1.1 0.036 
P12036 NEFH Neurofilament heavy polypeptide -3.0 < 0.001 -1.7 < 0.001 
P07196 NELE Neurofilament light polypeptide * -2.3 < 0.001 -1.3 < 0.001 
P07197 NEFM Neurofilament medium polypeptide * -2.1 < 0.001 -1.2 < 0.001 
Q15365 PCBP1 Poly C-binding protein 1 -1.4 < 0.001 -1.1 0.131 
Q9Y3C6 PPIL1 Peptidyl-prolyl cis-trans isomerase-like 1 1.6 0.002 -1.1 0.739 
P32119 PRDX2 Peroxiredoxin-2, isoform 1 * -1.4 < 0.001 -1.1 < 0.001 
P28072 PSMB6 Proteasome subunit beta type 6 1.7 0.001 -1.1 0.861 
P84095 RHOG RhoG -1.6 < 0.001 1.1 0.713 
Q15019 SEPT2 Septin 2 -1.2 < 0.001 -1.1 0.087 
Q99719 SEPT5 Septin 5 -0.7 < 0.001 -1.2 < 0.001 
Q16181 SEPT7 Septin 7 -1.6 < 0.001 -1.2 < 0.001 
Q92599 SEPT8 Septin 8* -1.3 < 0.001 -1.1 0.271 
Q9UHD8 SEPT9 Septin 9 -1.3 < 0.001 -1.1 0.619 
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Q9NVA2 SEPT11 Septin 11* -1.4 < 0.001 -1.2 0.001 
Q9C0H9 SRCIN1 SRC kinase signalling inhibitor 1 1.6 < 0.001 0.0 0.856 
Q92777 SYN2 Synapsin 2 * 1.2 < 0.001 1.5 < 0.001 
P68366 TUBA4A Tubulin -4A chain -1.4 < 0.001 0.0 0.912 
P04350 TUBB4A Tubulin -4A chain -1.3 < 0.001 1.1 0.160 
Q99726 SLC30A3 Zinc transporter 3 * -1.7 < 0.001 1.2 0.511 
P60520 GABARAPL2 
-aminobutyric acid receptor-associated protein-like 
2 
-1.2 0.144 -1.4 < 0.001 
Q13423 NNT NADP transhydrogenase, mitochondrial 0.0 0.665 1.4 < 0.001 
Q99536 VAT1 Vesicle amine transport 1 0.0 0.601 1.2 < 0.001 
Q9Y2I8 WDR37 WD repeat-containing protein 37 -1.2 0.040 -1.1 0.687 
O94811 TPPP Tubulin polymerization-promoting protein * -1.6 < 0.001 -1.3 < 0.001 
Q9Y2J0 RPH3A Rabphilin-3A * -2.6 < 0.001 1.9 < 0.001 
P36957 DLST 
2-oxoglutarate dehydrogenase complex component 
E2, mitochondrial * 
-1.5 < 0.001 -1.3 < 0.001 
Note: Each protein is listed with SwissPort accession number, sequence coverage, log2 fold change (significant if value is greater than ± 0.3), and P 
value (generated by MSstats statistical software; significant are in italics). * have been implicated in AD in previous studies.  
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Figure legends 
Fig. 1. Overview of SWATH acquisition. The first quadrupole (Q1) is stepped continuously with 
m/z window of 25 amu across the entire m/z range of interest. All fragment ions generated 
by collision-induced dissociation in the second quadrupole (Q2) are monitored by the ToF 
mass analyser. 
Fig. 2. Top canonical pathways from IPA core analysis 
Fig. 3. Pathway analysis. Identified proteins are shaded. TPPP, tubulin polymerization-promoting 
protein; Tubb4a, tubulin 4A class IVa; PSEN1, presenilin 1; NEFM, neurofilament 
medium polypeptide; TUBA4A, tubulin 4A chain; TUBB4B, tubulin 4B chain; 
TUBB3, tubulin 3 chain; NEFH, neurofilament heavy polypeptide; NEFL, 
neurofilament light polypeptide; Slc6a17, solute carrier family 6 member 17; DLST, 
dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial; TUBB4A, tubulin 4A chain; UBC, ubiquitin C; 
SIRT7, sirtuin 7; SYN2, synapsin 2; INA, internexin; SRRM2, serine/arginine repetitive 
matrix 2; PPIL1, peptidylprolyl isomerase-like 1; NNT, nicotinamide nucleotide 
transhydrogenase; CNTN2, contactin 2; RPH3a, rabphilin; SEPT2, septin 2; SEPT5, septin 
5; SEPT7, septin 7; SEPT8, septin 8; SEPT9, septin 9; SEPT11, septin 11; SEPT12, septin 
12; GABARAPL2, GABA(A) receptor-associated protein-like 2. 
Fig. 4. Triply charged peptide NLLHQDAVDLFR from synaptojanin-2-binding protein. a) Spectral 
peaks detected at SWATH window 474.0 to 500.0 m/z between 13.8-21.2 min. Blue arrow 
points to spectral peaks that PeakView software selected. Black arrow points to spectral 
peaks that actually belong to the target peptide. b) MS/MS spectrum at 16.9 min. Blue 
represents the spectrum from the SWATH data and the matching peaks are displayed in pink. 
c) Peptide fragments. d) MS/MS spectrum at 17.6 min. Peaks that could be identified at 
theoretical fragment ion m/z value are marked with black rectangular boxes. 
Fig. 5. Peptide ESIDLVLDR from tubulin 8 chain. a) Spectral peaks detected in SWATH 
window 524.0 to 550.0 m/z between 15.0-23.0 min. Blue arrow points to spectral peaks 
eluting at 20.9 min, which the PeakView software selected. Black arrow points to peaks 
eluting at 15.9 min, which the reference map suggests. b) MS/MS spectrum at 20.9 min. 
Blue represents the spectrum from the SWATH data and the matching peaks are displayed in 
pink. c) Peptide fragments. Peaks identified at theoretical fragment ion m/z value are marked 
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with black rectangular box 
Fig. 6.   Spectral peaks and MS/MS spectrum detected for internexin. Peptides ALEAELAALR 
2+ a) AD hippocampus, b) AD motor cortex, c) non-AD hippocampus, d) non-AD motor 
cortex; SNIEETTISSQKI 2+ e) AD hippocampus, f) AD motor cortex, g) non-AD 
hippocampus, h) non-AD motor cortex; KVESLLDELAFVR 3+ i) AD hippocampus, j) 
AD motor cortex, k) non-AD hippocampus, l) non-AD motor cortex; 
TIEIEGLRGANESLER 3+ m) AD hippocampus, n) AD motor cortex, o) non-AD 
hippocampus, p) non-AD motor cortex. 
Fig. 7. Spectral peaks and MS/MS spectrum detected for synapsin 2. Peptides 
VLLVVDEPHADWAK 3+ a) AD hippocampus, b) AD motor cortex, c) non-AD 
hippocampus, d) non-AD motor cortex; SFRPDFVLIR 3+ e) AD hippocampus, f) AD 
motor cortex, g) non-AD hippocampus, h) non-AD motor cortex; EMLTLPTFPVVVK 3+ 
i) AD hippocampus, j) AD motor cortex, k) non-AD hippocampus, l) non-AD motor 
cortex; VLLVVDEPHADWAK 2+ m) AD hippocampus, n) AD motor cortex, o) non-AD 
hippocampus, p) non-AD motor cortex. 
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Fig. 4 
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Fig. 5 
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Fig. 6 
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Fig. 7 
 
P a g e  | 176 
 
P a g e  | 177 
 
P a g e  | 178 
 
P a g e  | 179 
 
P a g e  | 180 
 
P a g e  | 181 
 
P a g e  | 182 
 
P a g e  | 183 
 
P a g e  | 184 
 
P a g e  | 185 
 
P a g e  | 186 
 
P a g e  | 187 
 
P a g e  | 188 
 
P a g e  | 189 
P a g e  | 190 
 
  
  
 
 
 
 
Chapter 7 
Discussion and  
Future Directions 
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This chapter reviews and summarises the thesis, identify the main methods used, discuss its main 
findings and contributions, indicates limitations, and outlines future directions. The chapter is 
divided in to five sections. Section 7.1. is a summary of the thesis. Section 7.2. discusses the 
contribution of the current work. Section 7.3. presents a discussion of the limitations of this study. 
Section 7.4. discusses potential future directions. Section 7.5. brings the thesis to a conclusion. 
 
7.1. Summary of the Thesis 
The aim of the studies presented in this thesis was to use comparative proteomics-based 
techniques on the human synaptic proteome to investigate protein abundance differences in AD-
affected and relatively spared regions of human brain. Accumulating evidence supports that 
synaptic dysfunction and degeneration is a primary pathology for AD
1-3
; synaptic loss is the best 
correlate of cognitive decline in AD 
4
. The hypothesis of this project was that the synaptic proteome 
of a human brain with Alzheimer’s disease is different from that in normal ageing brain. Identifying 
abnormally expressed synaptic proteins will help elucidate molecular mechanisms underlying 
synaptic loss in AD. 
Broadly, chapter 2 reviewed the current literature on Alzheimer’s disease, synaptic 
pathology and neuroproteomics. This chapter covered societal burdens associated with AD, clinical 
symptoms, clinical and neuropathological diagnosis, and pathological hallmarks of AD. In addition, 
the basic biology of the synapse, including the structure and function, as well as synaptic pathology 
was covered. Furthermore, chapter 2 described neuroproteomics utilising various methods, from 
conventional 2-DE gel separation methods to more recently introduced MRM and SWATH-based 
mass spectrometry.  
Samples used in chapters 3, 4, 5 and 6 were prepared using subcellular fractionation to 
isolate synaptosomes from human autopsy tissue. Also, due to heterogeneity of human subjects and 
region-specific AD pathology, the severely affected areas (hippocampus and/or temporal cortex) 
were compared with relatively spared areas (occipital and/or motor cortices) within each AD and 
non-AD group. 
In chapter 3, synaptosomal fractions from AD brain and non-AD brain were compared 
using 2D-DIGE, a gel-based technique with fluorescent labelling. A total of 871 protein spots were 
detected on a 2DE gel. The relatively spared areas of AD brain were compared with that of non-AD 
brain, which showed that zero and one protein spot was significantly different in abundance in 
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motor and occipital cortices comparisons, respectively. These comparisons suggested that motor and 
occipital cortices of AD brain can be used as control regions for normalising the data. Another 
significant finding was that 26 unique synaptic proteins exhibited an abundance difference greater 
than two-fold between and AD and non-AD subjects. The protein spot identity was determined 
using either MALDI-ToF or ESI-QToF MS. Of these, synaptic vesicle-related proteins and 
structural proteins were selected for Ingenuity pathway analysis (IPA), which showed that those 
proteins are closely associated with each other. This network analysis also identified other closely 
interacting proteins. 
Chapter 4 presented a new method for targeted quantitative analysis of synaptosomal 
proteins from human autopsy tissue using label-free MRM with HPLC-triple quadrupole-linear ion 
trap MS. The protein enolase (Streptococcus pyogenes serotype M6) was used as an internal 
standard across samples by spiking an equal amount into each. As a proof of principle test, three 
synaptic proteins, synaptotagmin 1, cathepsin D and tubulin -1A chain, were analysed with four 
injections over four consecutive days with a CV value of <4%, and consistent retention time was 
reported across the replicates. The new method described in chapter 4 can be applied to target 
various synaptic proteins to study many different brain disorders, including but not limited to 
Parkinson’s disease, amyotrophic lateral sclerosis and lewy body dementia. 
The study described in chapter 5 utilised the MRM method presented in chapter 4 to target 
(i) proteins that exhibited significant abundance differences in 2D-DIGE analysis, and (ii) proteins 
that were found to be closely associated from IPA. The global abundance of ten synaptic proteins 
was estimated. The MRM assay was linear, and reproducible with CV value of <9%. Significant up-
regulation of peroxiredoxin-1 and dihydropyrimidinase-related protein-1 were found in AD 
hippocampus when compared with AD motor cortex. Significant down-regulation of peroxiredoxin-
1, creatine kinase B and fructose-biphosphate aldolase C were found in non-AD hippocampus when 
compared with non-AD motor cortex. The MRM data was contrasted with 2D-DIGE data, and 
found that the majority of abundance changes detected in 2D-DIGE analysis reflect those of 
isoforms with varying degrees of post-translational modifications or splice variants. 
The aim of this thesis was to study the synaptic proteome of human AD brain. Current 
understanding of the literature is that there are around 3000 proteins in the synapse. However, in-gel 
based 2-DE revealed only 871 protein spots, which included post-translationally modified isoforms 
and alternatively spliced forms. To quantitatively study a larger portion of the synaptic proteome, 
synaptosomal fractions were analysed using a gel-free method in which samples were SCX 
fractionated prior to the SWATH assay, which is described in chapter 6. SWATH-MS is a data 
P a g e  | 194 
independent acquisition method that generates a complete recording of all possible ions in a 
biological sample in a single analysis. This technique does not require sample-specific method 
development and provides high resolution quantification. A total of 2077 unique proteins were 
identified that have critical local false discovery rate of <5%. A total of 36 proteins showed 
significant differences in abundance between AD or non-AD hippocampus when compared with 
motor cortex, and displayed greater than 1.5-fold differences between AD log2FC and non-AD 
log2FC. IPA core analysis on these proteins revealed that the most affected molecular and cellular 
functions in AD hippocampus were cellular assembly and organization, cellular compromise, 
protein synthesis, and cellular function and maintenance.  
 
7.2. Contributions  
A growing body of evidence suggests that synapse degeneration and dysfunction is a more 
accurate correlate of cognitive decline in early AD
4
. Although major resources and funding have 
been allocated to AD research, the exact molecular mechanism underlying synaptic pathology is 
still unclear. I identified several novel proteins that are differentially regulated in the synapses of 
AD-affected brain region/s. The identified proteins may be involved in alteration of synaptic 
function, causing synaptic degeneration, and eventually neuronal death. Thus, these proteins are 
potential therapeutic targets that might prevent or slow AD progression. However, further functional 
studies need to be conducted to ensure the abundance differences are the “causative” factor; this is 
discussed in section 7.4.  
To our knowledge, this thesis contains the first study (chapters 4 and 5) to look at 
synaptosomal fractions from human autopsy brain using label-free MRM-MS. I described the 
quantitative assay for a set of low abundant synaptic proteins, including synaptotagmin 1 (a key 
player in exocytosis), cathepsin D and tubulin -1A chain in chapter 4, plus peroxiredoxin-1, 
dihydropyrimidinase-related protein 1, creatine kinase B, Go subunit  malate dehydrogenase, 
dihydropyrimidinase-related protein 2 and fructose-bisphosphate aldolase C in chapter 5. MRM 
requires far less amount of samples for protein identification and quantification compared with 2-
DE gel-based methods. Hence, MRM is suitable for studying low abundant proteins in scarce 
biological samples, such as human autopsy brain. As this method becomes more routine, 
empirically tested transitions established for each protein can be collected into a database for use by 
the scientific community. In addition, the protein extraction and sample preparation protocol 
developed for the MRM assay can be used as a template for developing further MRM-based studies 
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of other related proteins, as well as various neurological disorders.  
I analysed a pooled sample from AD and non-AD hippocampus and motor cortex using 
SWATH-based acquisition MS to generate spectral libraries for a reference map of the 
synaptosomal fraction of human autopsy brain. The reference map contains information, including 
peptide identifications for 2077 unique proteins, and precursor ion sequence, mass, change and 
chromatographic retention time, and fragment ion mass, charge and relative intensities for each 
peptide identified. Online repositories such as MacCoss Lab 
(http://proteome.gs.washington.edu/software/bibliospec/documentation/libs.html), Peptide Atlas 
(http://www.peptideatlas.org/speclib/), National Institute of Standards and Technology (NIST) 
(http://peptide.nist.gov/) and The Global Proteome Machine (GPM) 
(ftp://ftp.thegpm.org/projects/xhunter/libs/) have collections of spectral libraries freely available. 
However, a comprehensive spectral library of the synaptic proteome was not available. Upon 
publication of the SWATH analysis data, the generated reference spectral map will be freely 
available to researchers around the world for use in future studies on the synaptic proteome.   
Here, I have found that synaptic proteins related to synaptic structure, oxidative stress, 
vesicle maintenance, metabolism and proteolysis are differentially regulated in AD hippocampus 
compared with non-AD hippocampus. Previous studies have shown that all of these functions are 
affected in AD brain
4-7
. This study not only confirms that such functions are damaged, but also 
found novel proteins, which is listed in the discussion section of chapters 3, 5 and 6. In addition, I 
found that the most affected molecular and cellular functions in synaptosomal fractions from AD brain 
were cellular assembly and organisation, cellular function and maintenance, cell-to-cell signalling and 
interaction, cell morphology and cellular development.  
Both 2D-DIGE analysis and MRM assay revealed significant up-regulation of peroxiredoxin-1 
protein in AD hippocampus when compared with AD motor cortex. In non-AD comparisons, 2D-DIGE 
revealed no significant difference, and MRM assay showed significant down-regulation of this protein 
in non-AD hippocampus. Up-regulation of peroxiredoxin-1 reflects the severity of oxidative stress 
derived from free radicals in AD hippocampus. It is inferred that peroxiredoxin-1 up-regulation is a 
protective mechanism against free radical-induced oxidative stress.  
Another interesting protein to note is dihydropyrimidinase-related protein 2, a structural 
protein. Initial 2D-DIGE analysis showed significant up-regulation in AD hippocampus when 
compared with AD motor cortex, and no significant difference when non-AD hippocampus was 
compared with non-AD motor cortex. However, MRM analysis revealed no significant differences 
in both AD and non-AD comparisons. Such divergent result indicates that a post-translationally 
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and/or chemically modified form of dihydropyrimidinase-related protein 2 could be up-regulated, 
whereas the global protein abundance remained the same. Since PTM often controls protein activity, 
the function of dihydropyrimidinase-related protein 2 could be affected in the synapses of AD 
hippocampus.  
 
7.3. Limitations  
Currently, there are no adequate housekeeping proteins available for accurate normalisation 
of the data derived from synaptosomal fraction of AD brain. Although I used an internal standard 
for 2D-DIGE and MRM studies, and carried out sample protein quantification in triplicates, the 
presence of at least one housekeeping protein could strengthen the statistical power of the analysis. 
An advantage of using SWATH analysis was that the protein quantity could be normalised to the 
total amount of proteins present in the sample. Also, because human post-mortem brain is rare, I 
was limited to two affected areas and two spared areas from 6 AD and 6 non-AD cases. Increasing 
the sample size would provide a more accurate representation of the protein abundance differences, 
and give stronger p-values for greater statistical significance. 
 A major disadvantage of the 2D-DIGE analysis is that two or more proteins can be 
visualised as a single protein spot when their pI and molecular weight are the same, especially with 
highly complex protein mixtures. This introduces experimental error, making it difficult to 
accurately quantify global protein numbers and abundance. My initial 2D-DIGE analysis showed 
that inositol monophosphatase 1 abundance was 68.5% higher in AD hippocampus compared with 
AD motor cortex. Inositol monophosphatase 1 plays a role in providing inositol required for 
synthesizing phosphatidylinositol and polyphosphoinositides; altered level of abundance may affect 
cell signaling and membrane trafficking in the synapses. So, inositol monophosphatase 1 was 
targeted for validation using Western blotting, which showed 54% down-regulation in AD 
hippocampus when compared with AD motor cortex. Because Western blot and 2D-DIGE gave 
opposing results, the MS data was reanalysed, which revealed that cathepsin D preproprotein was 
also detected from the same protein spot as inositol monophosphatase 1. Previously, this protein 
was ignored because the mass of cathepsin D preproprotein is 45 kDa and inositol 
monophosphatase 1 is 30 kDa, and the protein spot was located near 30 kDa range. Uniprot 
database revealed that Cathepsin D preproprotein can be further processed down to light (10.7 kDa) 
and heavy chain (26.6 kDa)
8
. So, the true identity of protein spot seems to be cathepsin D – heavy 
chain, or a combination of both proteins (cathepsin D – heavy chain and inositol monophosphatase 
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1). There is a possibility that the abundance differences detected in some of the other proteins could 
be that of a different protein/s that migrated at the same spot; careful analysis of the MS data with 
higher levels of identification stringency is required to eliminate this possibility. In addition, 
because 2D-DIGE is a 2-DE-based technique, it is difficult to analyse proteins with high molecular 
weight or those that are hydrophobic, of low abundance and/or that have extreme isoelectric points. 
These characteristics limit 2D-DIGE’s usefulness as a discovery driven, global-protein analysis tool; 
however, it is still widely used by many researchers, and proves to be a powerful technique when 
used appropriately.  
 The development of SWATH data analysis has made quantitative and qualitative analysis of 
highly complex protein samples much easier with higher levels of accurate protein-identification. 
However, several limitations were identified. The software used to do the analysis, MS/MSALL 
with SWATH™ Acquisition MicroApp (version 1.0) required significant user intervention to ensure 
correct peak selection. The SWATH™ Acquisition MicroApp often selected an incorrect peak from 
the MS/MS spectrum. In addition, the observed retention time of precursor ions differed 
considerably with predicted retention time, and/or peptide MS/MS sequences could not be 
confidently matched to the theoretical sequence. The latter issue may be a result of low protein 
levels in the sample; thus, I excluded those peptides in the analysis as their identity could not be 
accurately verified. In the cases where the software made an error in selecting the peak derived 
from a proteotypic peptide, I was unable to make changes so that the correct peak was selected for 
the analysis. If the target protein had two proteotypic peptides, but one peptide had to be excluded 
due to the aforementioned reasons, the protein was excluded from the analysis. However, SWATH 
acquisition-based MS is a relatively new technique, and MS/MSALL with SWATH™ Acquisition 
MicroApp is only version 1.0. Hence, more advanced versions will most likely be released with 
added features and capabilities to overcome these limitations. Alternative software is OpenSwath 
(http://www.openswath.org/)
9
. OpenSwath has been used by Gillet and colleagues
10
, and although it 
is yet to be explored, it may have better peak picking capabilities. A major advantage of SWATH is 
that the data collected in this study can be re-analysed with upgraded software packages as they are 
released to identify new protein targets without the need to run new samples.  
 
7.4. Future directions 
Here, I identified several proteins that showed significant abundance differences in AD-
affected areas of human brain. These include, from the 2D-DIGE analysis: v-type proton ATPase 
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catalytic V1 subunit A, annexin V, septin 8, tubulin polymerization-promoting protein, septin 11, 
dihydropyrimidinase-related protein 1, pyruvate kinase isoform M1, malate dehydrogenase, creatine 
kinase B, peroxiredoxin 1, rab GDP dissociation inhibitor   guanine nucleotide dissociation 
inhibitor 1 and UBXD6; from SWATH analysis: septins 2, 3, 5, 7, 8 isoform 1 and 9, cadherin-13, 
NFM, tubulin -4A chain, tubulin -4A chain, poly C binding protein, versican, RhoG protein, SRC 
kinase signalling inhibitor 1, - aminobutyric acid receptor-associated protein-like 2, mitochondrial 
NADP transhydrogenase, proteasome subunit beta type-6, vesicle amine transport 1, WD repeat-
containing protein 37 and peptidyl-prolyl cis-trans isomerase-like 1. While the identification of 
these proteins is significant, there are several areas of investigation that can be followed as 
consequence of, or to enhance, this study. 
Firstly, now that I have developed a robust methodology for SWATH analysis, larger 
sample sizes should be tested. By increasing the number of cases in the study, some observed 
changes in protein levels which were trending, but not significant, will gain statistical power and 
may show a significant difference. Hence, additional proteins altered in the AD brain may be 
identified. In addition, for future research, the findings from SWATH assay could be validated using 
other techniques such as Western blotting or MRM. Due to restricted time, validation could not be 
conducted in this study. As discussed in section 7.3, the retention time issues with SWATH™ 
Acquisition MicroApp could make it technically challenging. To overcome this problem, alternative 
software, such as OpenSWATH, could be used, as well as commercially available synthetic peptide 
standards. Secondly, functional studies on proteins identified in this study would help determine 
whether these differences are the “causative” factor of synaptic pathology, or the result. This could 
be done by studying neuronal cell cultures or transgenic animals with the target protein either 
overexpressed or knocked-down. If the abundance changes are the “causative” rather than “as a 
result”, then the protein will become a strong candidate for therapeutic marker.  Other “as a result” 
proteins could be of interest as a biomarker if similar changes could be replicated in plasma or CSF. 
In addition, it would be interesting to see how the protein-protein interactions identified from IPA 
analysis are affected in AD, particularly for proteins identified as therapeutic candidates.  
ProteinPilot search engine that was used to analyse SWATH data acquired in IDA mode 
searches peptides with missed and unexpected cleavages. This can provide invaluable information 
about the reliability of identification results. By monitoring such digestion deviations, it is possible 
to check whether the digestions are working well and reproducibly. Due to time constraints, such 
monitoring could not be conducted, and is left for future research. 
The spectral library generated in this study was created by acquiring full scan MS/MS data 
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of all the analytes present in the sample mixture. The targets were mined post-acquisition. So, when 
new a hypothesis or new data processing tools are developed, it is possible to go back and 
reinterrogate the data and uncover answers using the same spectral library originally generated. This 
retrospective mining capability of SWATH assay is extremely advantageous as compared to MRM 
assays. For future studies, it would be interesting to mine the SWATH data to look at proteins 
involved in transport, docking and fusion of synaptic vesicles, and other proteins that I was unable 
to explore and check individual peptides and transitions, due to time constraints. Also, a new 
spectral library containing PTMs can be generated using the existing SWATH data to study the 
abundance changes of post-translationally modified proteins in AD. This would greatly help in 
understanding the synaptic pathology underlying AD. 
 
7.5. Conclusion 
 In conclusion, this thesis has contributed to the understanding of the synaptic proteome and 
changes in protein abundance in AD brain within that proteome. In addition, I established a 
technique for accurately and reproducibly analysing low abundant synaptic proteins from human 
brain tissue using MRM, and the more recently introduced SWATH MS assay. To the best of my 
knowledge, study described in chapter 6 presents the first application of SWATH to 2D separated 
samples.  
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